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ABSTRACT 
Two separate assays for prizidilol have been developed. One relies 
on separation by high performance liquid chromatography, and the 
other on separation by thin layer chromatography. Both of these 
methods have several advantages over the existing assay developed 
by JC Pearce for Smith Kline and French Ltd. (SK & F). 
Firstly, both methods utilize pepsin to digest plasma protein since it 
is known that precipitation with trichloroacetic acid of the protein 
leads to losses by binding at different rates of prizidilol and of the 
internal standard. The SK & F assay might therefore be less sensitive 
and precise than necessary. Secondly, use of the complexing reagent, 
quinolin-3-al, leads to greater sensitivity of detection than the reagent, 
anisaldehyde, previously employed. The minimum level of quantitation 
of the developed assays are approximately 30 µg/1 by HPLC and 15 µg/1 
by TLC, as against 50 µg/1 by the earlier HPLC method originating from 
SK & F laboratories. Finally, the TLC method is much quicker to 
perform than the previous assay. 
The biotransformation of prizjdilol by hepatic cytochrome P-450, 
glutathione S-transferases and acetyltransferases has been investigated. 
The hepatic microsomal cytochrome P-450 enzyme system is capable of 
binding and metabolizing prizidilol. Prizidilol is shown to bind to 
two distinct sites on cytochrome P-450. At low concentrations (<23.7 µM) 
prizidilol binds to the type I site (active site) of the enzyme. In 
contrast, at higher concentrations (24 - 190 µM), prizidilol binds 
to the type II site (oxygen binding site) of the enzyme. 
XI 
The apparent binding constants (Ks), maximum extents of binding 
(6Amax), Michael is constants (Km) and maximum velocity (Vmax) for the 
interaction of prizidilol with hepatic microsomal cytochrome P-450 
were assessed in differently pretreated rats. Rats were pretreated 
with inducing agents viz., phenobarbital, S-naphthoflavone and 
pregnenolone-16a-carbonitrile each of which specifically elevates 
the levels of a selected form of cytochrome P-450. Binding constants 
for binding to the type I site Michaelis constants were in all cases 
in the range of l to 5 µM. The binding constant for binding to the 
type II site was ca. 100 - 300 µM. The observed effect of induction 
on 6A and V suggests that several of the multiple forms of max max 
cytochrome P-450 bind and metabolize prizidilol. 
The biotransformation in vitro of prizidilol was shown to be inhibited 
by metyrapone, SK & F 525-A and C0:02 (80:201), which are all effective 
inhibitors of cytochrome P-450. In contrast, the hepatic cytosol 
GSH S-transferases did not catalyze the metabolism of prizidilol: No 
loss of prizidilol was seen with liver cytosol plus GSH. 
Acetylation was found to play a significant role in prizidilol metabolism. 
Enzymatic acetylation of prizidilol was found following incubation of 
the substrate and acetyl CoA with rat liver cytosol or partially puri-
fied N-acetyltransferase. The levels of cyclised acetylated product 
were significantly increased following incubation. The acetylation 
of prizidilol was inhibited by cuprous chloride and manganese sulfate, 
which inhibit acetyltransferase. The K for the acetylation of prizi-m 
dilol was 0.78 wM and the maximum velocity of the reaction (Vmax) 
was 0.98 µmol/mg protein/min. 
acetyl CoA was 22 ± 0.17 µM. 
Limiting value of the apparent K for 
m 
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1. INTRODUCTION 
1.1 Hypertension 
Hypertension, that is, an abnormal increase in blood pressure 
within arteries and arterioles, is a very common disorder in 
industrialized societies, generating a multitude of vascular compli-
cations which may be fatal. 
According to the World Health Organization, normal blood pressure and 
hypertension may be defined as follows: 1. an adult is normotensive 
when his or her systolic arterial pressure is below 140 mm Hg and 
when his or her diastolic arterial pressure is below 90 mm Hg; 
2. an adult is hypertensive when his or her systolic arterial pressure 
is above 160 mm Hg and/or when his or her diastolic arterial pressure 
is above 95 mm Hg; 3. when systolic arterial pressure lies between 
140 and 160 mm Hg and diastolic arterial pressure between 90 and 95 
mm Hg, the term 'borderline' hypertension is employed. There are 
several varieties of hypertension. The first is permanent hypertension 
where both systolic and diastolic arterial pressures are permanently 
above normal values; certain clinical and biological signs permit the 
classification of permanent arterial hypertension into categories of 
benign or malignant. The second is labile hypertension, characterized 
by an occasional elevation of systolic or diastolic arterial pressure, 
or both. Situations leading to these transient increases in arterial 
pressure appears to be mainly associated with psychic tension or 
physical effort. Some forms of hypertension are secondary to a definite 
cause, such as a disorder of a kidney or adrenal gland, and in certain 
instances may be corrected surgically. However, in the great majority 
of cases of hypertension, no precise causal anomaly can be detected. 
This form of hypertension, whose pathogenesis remains unclear, is 
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termed essential hypertension. A large number of different 
therapeutic agents is today available for the control of hypertension. 
Amongst other approaches clinical studies have shown the effectiveness 
of combined treatment with a vasodilator and a s-adrenoceptor 
antagonist in the long term control of essential hypertension (l, 2). 
1.2 s-adrenoceptor blocking agents 
The finding that the relative potency of a series of sympathomimetic 
amines varied with the effector organs or systems led Ahlquist (3) 
to conclude that there are two distinct types of adrenergic receptors 
viz. the alpha and the beta receptors. The beta adrenergic receptors 
can be subdivided pharmacologically into beta1 (predominantly in 
heart) and beta 2 (predominantly in smooth muscle) on the basis of 
the relative selective effects of both agonists and antagonists on 
these receptors (4-7). The introduction of s-adrenoceptor blocking 
drugs into clinical practice has provided one of the most significant 
advances in the medical management of cardiovascular disease during 
the past 20 years. While the original investigators envisaged the use 
of these agents for the treatment of angina pectoris (8-10), hyper-
tension (11-13) and arrhythmias (14, 15), their therapeutic benefits 
have extended well beyond the cardiovascular sphere. For instance, 
the s-blockers have been utilized in the treatment of porphyria, 
anxiety and other neuropsychiatric conditions. In short, fe\'J synthetic 
drugs have had such widespread applicability in human pharmacology (7). 
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1.3 Propranolol 
s-adrenoceptor antagonists, of which propranolol hydrochloride 
(l-isopropylamino-3-(1-naphthyloxy) propan-2-ol hydrochloride) (Fig. 1) 
is the most widely used example specifically antagonizing catecholamine 
activation of s-adrenoceptors. 
Fig. 1 Structural formula of propranolol 
Propranolol, in common with all others-antagonists, binds to s-adreno-
ceptors in a competitive manner. Propranolol is a non-selective 
s-antagonist although recent studies suggest that it might be slightly 
s 2 selective (16). The drug does not modify the effects of histamine, 
acetylcholine or a-adrenoceptor agonists. More importantly, it does 
not interfere with the inotropic actions of cardiac glycosides, calcium 
or glucagon (17). Propranolol (0.17 mg/kg i.v.) in normal supine 
subjects reduces heart rate, cardiac output, mean arterial pressure, and 
left ventricular work (18). The degree of drug-related alteration 
of these parameters depends on the extent of adrenoceptor activation; 
the greatest hemodynamic change is observed when propranolol is given 
during submaximal exercise (18). Under such circumstances, the 
following average reductions have been observed: heart rate, 20%; 
cardiac output, 20:\; mean arterial pressure, 15·;; left ventricular 
work, 34;;; and myocardial consumption, 6;; (18). Propranolol causes a 
reduction in the indices of left ventricular contractility such as peak 
left ventricular dp/dt max and velocity cf fiber shortening, resulting 
in a reduction in peak systolic pressure at rest and on exercise. 
It also alters the pattern of regional myocardial contractile activity 
(19). In addition, propranolol reduces coronary blood flmv by 15 to 
25.:o and this is secondary to the reduction in myocardial oxygen 
consumption. Blood flow in the splanchnic and renal vascular beds is 
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also reduced secondary to systemic hemodynamic changes (20). 
Propranolol, in contrast with a-adrenoceptor antagonists, reduces the 
renal release of renin from the juxtaglomerular apparatus resulting 
from sympathetic nerve stimulation or catecholamine infusion (21). 
Hypertensive patients with elevated plasma renin activity generally 
shov, a satisfactory hypotensive response to propranolol (22), although 
this effect has also been noted in normoreninaemic hypertensive patients 
(23). During prolonged oral therapy with propranolol in hypertensive 
patients, the reduction in heart rate is maintained, but the peripheral 
vascular resistance, which initially rises, is likely to fall over a 
period of time despite a sustained satisfactory hypotensive response. 
The explanation for this is unknown and has been the subject of conside-
rable debate (24). 
In approximately 50~ of patients with mild to moderate hypertension, 
a satisfactory hypotensive response is obtained following the adminis-
tration of propranolol alone, and the fall in pressure generally occurs 
gradually over a period of several weeks (25). However, when employed 
in combination with a peripheral vasodilator such as hydralazine, an 
additive antihypertensive effect may be obtained and a satisfactory 
reduction in blood pressure can usually be achieved in 80% or more of 
patients (26). S-blocking agents have been used to prevent the reflex 
tachycardia induced by hydralazine (27). When vasodilators are given 
alone they tend to cause a reflex increase in cardiac function and in 
the circulating plasma renin level. Both these unwanted pharmacological 
effects are likely to be prevented by concurrent propranolol or other 
s-adrenoceptor blocker administration and several studies have shown that 
this is an effective form of antihypertensive therapy (28). 
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The widespread use of beta-blockers in recent years has been associated 
with an increasing incidence of adverse reactions, mostly due to 
excessive pharmacological action from inappropriate or excessive dosage 
(29). Special caution is needed in the elderly and patients with 
sinus bradycardia (<55 beats/min), heart block, cardiac enlargement (30), 
angina pectoris and bronchial asthma, airways obstruction. Patients 
with chronic lung disease are at risk of a reduced respiratory centre 
response to CO2 when they are treated with 
propranolol (31). This may 
precipitate respiratory failure. Propranolol also may cause severe 
bronchospasm in patients with asthma (32). A common cardiovascular 
effect of s-blockade is the development of cold extremities and Raynaud's 
phenomenon. The mechanism is probably due to the combination of a reflex 
increase in a-adrenoceptor vasoconstriction due to reduced cardiac 
output and blockade of vascular S-adrenoceptors with unopposed a-adrener-
gic effect on small arterioles. The most common nonspecific effects 
are generalised fatigue and gastrointestinal disturbance. 
1.4 Direct acting vasodilators 
Drugs that reduce the arteriolar smooth muscle tone directly are known 
as vasodilators. All the vasodilator drugs act at receptor sites to 
reduce peripheral vascular resistance but share a tendency to produce 
reflex tachycardia and fluid retention. A rise in plasma renin is 
usual after vasodilator drugs, related to the control level and pro-
bably representing a reflex response to the fall in the blood pressure 
(33). The first effective vasodilator in the treatment of high blood 
pressure was hydralazine. 
The effectiveness of hydralazine is limited by sympathetically mediated 
reflex tachycardia and an increase in cardiac output (34-36). Concomi-
tant administration of a B-blocker (e.g. propranolol) increases the 
6 
clinical usefulness of hydralazine by blocking reflex tachycardia 
and by potentiating its hypotensive action, thus allowing the use of 
smaller doses of hydralazine (2). 
1.5 Hydralazine 
Hydralazine (1-hydrazinophthalazine, Fig. 2) containing a hydrazine 
group is a long-acting vasodepressor agent. Original observations in 
man suggested that this drug was capable of lowering blood pressure 
while at the same time increasing renal plasma flow (37). 
5 10 4 6a;~N3 
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Fig. 2 Structural formula of hydralazine 
Hydralazine is a peripheral vasodilator. This drug exerts its antihyper-
tensive action by producing vasodilatation of the precapillary resistance 
vessels by direct relaxation of the arteriolar smooth muscle (38). 
Hydralazine has little or no effect on postcapillary venous capacitance 
vessels (39). The cellular mechanism by which hydralazine acts may 
be related to its ability to chelate trace metals,especially copper, 
which may be required for smooth muscle contraction (40, 41). Hydralazine 
also inhibits several enzyme systems including dopa decarboxylase and 
histidine decarboxylase (42, 43) and inactivates the two peptide presser 
substances pherentasin and angiotensin (44). In addition, hydralazine 
reverses or blocks the vasopressor effect of many substances such as 
norepinephrine, epinephrine, histamine, vasopressin, barium salts, etc., 
suggesting a direct effect on the arteriole resembling that of the 
nitrites. However, it is likely that the reduction in blood pressure 
is sensed by the baroreceptors resulting in an increased sympathetic 
discharge from the vasomotor center. A direct sympathetic effect on 
cardiac output and heart rate, blocked by propranolol and preceding 
the fall in blood pressure induced by hydralazine has been demonstrated 
(45). 
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Hydralazine has two distinct effects on the cardiovascular system: 
a decrease in peripheral vascular resistance and an increased cardiac 
output. A decrease in smooth muscle tone occurs predominantly in the 
arterial (small arteries and arterioles) and not the venous 
circulation and leads to a reduction of total peripheral vascular 
resistance (45, 47). Cardiac output and heart rate elevations accompany 
the arterial vasodilation, but there is little orthostatic hypotension 
due to the lack of effects of hydralazine on capacitance vessels (48). 
Although peripheral vasodilation is produced throughout the vascular 
beds, with substantial increase in flow to the splanchnic, renal, 
coronary, and cerebral vascular beds, flow to cutaneous and muscle 
beds shows variable changes depending on the level of blood pressure 
reduction (49, 50). 
A number of serious toxic side effects has limited the therapeutic 
usefulness of hydralazine. Nevertheless, the combination of hydralazine 
with other hypotensive agents (especially with a diuretic and as-
adrenoceptor antagonist) has proved effective (2). A s-adrenoceptor 
antagonist such as propranolol given simultaneously with hydralazine 
reduces the sympathetic mediated reflex increase in cardiac output and 
may alleviate certain of the haemodynamic side effects of hydralazine and 
potentiate its hypotensive activity. Hydralazine has also been 
employed successfully in the treatment of acute hypertensive emergencies 
(51) and congestive heart failure (52). 
Because of the side effects associated with high doses of hydralazine 
it is recommended that the total daily dosage should not exceed 300 mg 
(53, 54). Many of the undesirable effects of hydralazine are due to 
vasodilatation and reflex haemodynamic changes which include tachycardia, 
palpitation, headache, flushing, nasal congestion, angina pectoris or 
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even myocardial infarction in patients with pre-existing coronary 
artery disease. An increased incidence of joint pain and a lupus 
erythematosus-type syndrome is found during hydralazine therapy, 
especially if the patient has a past history of rheumatoid problems. 
The incidence of this toxicity approaches 10 to 20'; in individuals 
treated with 400 mg per day or more. With doses under 200 mg daily, 
toxicity has only rarely been reported in some series (54), but has 
occurred at doses of 100 mg daily in others (55). The lupus-like 
syndrome is almost always associated with circulatory antinuclear 
antibodies and is more common in Caucasians and slow acetylators of 
drug (54). 
1.6 Prizidilol 
The aim in the design of this drug molecule was to provide a vasodilator 
while attempting at the same time to avoid undesirable reflex effects 
such as tachycardia and increased cardiac output. The molecule 
closely resembles a combination of propranolol and hydralazine, 
as indicated by its structure which is shown in Fig. 3. 
/"OCHzCH(OH)CHzNHC(CH3)3 
·-· ·-· 
/ '--•~ ~-NHNH2 
'\ .I' " / •=• N=N 
Fig. 3 Structural formula of 
prizidilol 
This drug has a minimal effect on capacitance vessels. The diastolic 
blood pressure falls more than the systolic pressure, which suggests 
that the drug is acting predominantly by vasodilatation (56). 
Prizidilol is a potent and competitive s-adrenoceptor antagonist but, 
unlike propranolol, it does not appear to enter the central nervous system 
or to have significant local anaesthetic activity; prizidilol does have 
weak intrinsic sympathomirnetic activity (less than oxprenolol) (56). 
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Experiments in cats, rats and dogs have confirmed that prizidilol 
(2 to 4 mg/kg i.v.} causes a pronounced peripheral vasodilatation, 
particularly of the arterioles, the renal, coronary and skeletal muscle 
vasculatures, with a redistribution of the cardiac output (56, 57). 
Acute, subacute and long-term chronic studies in mice, rats and baboons 
have not revealed any clear evidence of toxicity. High doses of 
prizidilol administered for long periods of time to various experimental 
animals, notably rodents and baboons, have produced brown discolouration 
of certain tissues and organs, particularly the liver and mesenteric 
lymph nodes but not the central nervous system. This pigmentation was 
not seen at lower dose levels, including intravenously, nor after short 
periods of exposure to the compound. It is only present in animals 
administered considerable quantities of the drug for extended periods 
of time (more than 100 mg/kg per day) (58). 
Studies on healthy volunteers using isoprenaline infusion indicated 
that prizidilol causes beta-blockade in man and has a potency 10% 
that of propranolol on a miligram weight for weight basis (59). The 
clinical evidence is good in that both properties of the drug, namely the 
beta blocker activity and hydralazine effect, are manifest at the same 
dose (59). Prizidilol did not have significant effect on glucose 
tolerance, serum insulin, lipid profile, 24-hour urine electrolyte 
excretion, aldosterone and plasma renin activity, cerebral blood flow 
and renal blood flow (56, 60, 61). One-hundred-and-seventeen healthy 
subjects had taken part in studies with prizidilol. One case of cardiac 
arrhythmia was reported after administration of prizidilol but no 
other adverse effects have been noted. Forty-two patients had received 
the drug for up to sixteen weeks. Drop-out rate was low and adequately 
accounted for. None of the drop-out events recorded appear to have 
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been directly attributable to administration of prizidilol. Isolated 
fall in platelet count did not appear to be attributable to the 
administration of prizidilol (56). 
Records of 97 patients with mild to moderate essential hypertension 
treated for up to 48 weeks demonstrated the antihypertensive efficacy 
of prizidilol. Three patients withdrew from the study because of side 
effects probably related to the drug (bronchoconstriction-2, nausea 
and vomiting-1) (61-63). It would appear that patients who are slow 
acetylators may require a comparatively smaller dose of prizidilol 
for satisfactory control of blood pressure than fast acetylators. This 
observation needs to be confirmed in chronic studies (56). 
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2. ANALYSIS 
The published techniques for the quantitative determination of propranolol 
and for hydralazine are outlined in the following sections since they 
were felt to be relevant, at least potentially, to the analysis of 
prizidilol. Indeed, the standard SK & F (unpublished) method for the 
drug (81) is derived from an assay for hydralazine (73). 
2.1 Discussion 
2.1.1 Propranolol assay 
The original assay method for propranolol was based on fluorimetry 
(64). More recently, the techniques of high performance liquid 
chromatography (HPLC) (65) and thin-layer chromatography (TLC) have 
been applied to the assay of propranolol (66), although both tech-
niques still rely on fluorometric detection. The HPLC assay has been 
compared directly with the spectrofluorometric assay and the former 
gives better results only when a plasma blank is not available for 
each subject (67). Other assay techniques that have been described 
are: gas chromatography-mass spectrometry (GC-MS) (68); gas chroma-
tography with a 63N; electron-capture detector (69); inmunoassay 
based on specific antisera to propranolol or its isomers (70) and 
radioreceptor assay (71). 
2.1.2 Hydralazine assay 
Three different methods have been used to measure hydralazine in the 
plasma of human subjects; spectrophotometry (72, 73), radioisotope 
dilution analysis (74) and gas chromatography (75). These methods 
have a common denominator. Since hydralazine can not be extracted 
from biological material without decomposition, all methods rely on 
the formation of a derivative of hydralazine prior to extraction and 
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quantification. The spectrophotometric method, where hydralazine is 
derivatized with p-hydroxy or p-methoxybenzaldehyde to form the 
hydrazone (Fig. 4), lacks sufficient sensitivity to measure hydralazine 
plasma levels following low doses of hydralazine. In the gas chroma-
tographic method, hydralazine is treated w.ith nitrous acid to form 
tetrazolophthalazineo This method is of high sensitivity, providing 
a detection limit of about 0.063 M (10 µg/1) hydralazine in plasma. 
The use of 4-methylhydralazine as internal standard guarantees the 







Fig. 4 Structural formula of 
pyruvic acid hydrazone 
N 
The accuracy of the method is questionable, however, since hydralazine 
readily forms hydrazones with endogenous ketones in vivo and in vitro. 
These hydrazones are unstable under the acid condition which had 
been employed for hydralazine assay, but are partially reconverted to 
parent drug. As a result the values for hydralazine were found to be 
incorrectly high (76, 77). This is because acid labile conditions 
of the derivation procedure and only an "apparent hydralazine 11 level 
is obtained. Two modifications of specific high-performance liquid 
chromatographic assay have been reported for hydralazine and its 
metabolite (78, 79), hydralazine pyruvic acid hydralazone, 5-triazolo-
3,4a-phthalazine, 3-hydroxymethyl and 3-methyl-5-triazolo-3,4a-
phthalazine in human plasma. 
2.1.3 Prizidilol assay 
Assay for prizidilol in blood serum is challenging because the compound 
is poorly stable at room temperature at neutral pH and decomposes very 
rapidly above pH 10 (239). Although it is a base (pKa 5.4 and 9.85), 
extraction into organic solvents under alkaline conditions is ineligible 
unless the hydrazine- moiety is previously reacted, for instance, with 
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an aromatic aldehyde. Furthermore, the drug forms at least two 
metabolites in man of unknown activity: the "acetyl metabolite", 
by acetylation of the hydrazino- moiety, and the "pyruvic acid 
hydrazone". These revert back to the parent drug when heated at 70° 
at pH l for one hour to the extent of 22-29% and 69-78% respectively 
(239). The conditions quoted are those used in the standard assay 
(81). Lastly, if plasma protein is precipitated using trichloroacetic 
acid, the recoveries of the anisaldehyde hydrazones of prizidilol and 
of the internal standard (81) are respectively 37% and 32% after one 
minute and 31% and 21% after 10 minutes (239). 
In view of the foregoing difficulties, it seemed improbable that the 
standard method for the assay of prizidilol (81; see section 2.2.2) 
would be either specific or accurate. Since it included a deliberate 
(but not wholly successful) attempt to hydrolyse the acetyl and pyruvyl 
metabolites entirely, it was unclear what relationship the concentration 
measured in a sample would bear to the concentration of prizidilol 
actually present. Furthermore, although recommendations were made to 
separate protein precipitated by trichloroacetic acid from supernatant 
as quickly as possible so as to minimise drug loss of drug and internal 
standard, the loss would nevertheless be high. A belief current among 
analysts, but based admittedly on anecdotal evidence, is that assays 
with low drug recoveries tend to be unpredictably inaccurate; this is not 
supported in this thesis or the work of Pearce (81) but an attempt 
to correlate results from five different laboratories each using 
essentially Pearce's technique was only partially successful (239). 
There was therefore some justification for attempts to devise new 
analytical methods for prizidilol. 
The approach adopted for the extraction was made with the problems 
discussed above in mind. In a single step, plasma protein was digested 
using pepsin (so a precipitation step was unnecessary) and the 
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derivatisation was performed using quinolin-3-al (arbitrarily chosen) 
under mild conditions (pH 3, 45° for 45 min) which did not lead to 
detectable hydrolysis of either authentic acetyl or pyruvyl metabolites. 
The reaction mixture was alkalinised and the quinolinal hydrazones 
were extracted into dichloromethane, which was separated and evaporated 
to dryness (see section 2.2.3). 
Two approaches for detection of prizidilol were pursued simultaneously, 
by HPLC and by TLC, since it was not clear which method would be 
superior. The HPLC technique (see sections 2.2.4) was a trivial 
modification of that of Pearce (81), but the TLC method was novel in 
several ways: firstly, the sensitivity of detection was increased by 
choice of a suitable solvent for sample application (for which the 
prizidilol derivative has a low Rf value) and maximising the proportion 
of extract applied; secondly, interference by other compounds present 
in the extract was minimised by using a pre-washing solvent (for which 
also the prizidilol derivative has a low Rf value); thirdly, accuracy 
and reproducibility were improved by using the internal standard 
(uncommon procedure in TLC). Although the TLC assay was more difficult 
to develope than the HPLC version, TLC densitometry should have the 
following advantages: it is cheap in materials; the stationary phase 
can be pre-washed and is disposable; it is a batchwise rather than 
sequential assay and would therefore normally be more rapid in the 
analysis of large numbers of samples than HPLC. 
2.2 Methods and results 
2.2.1 Validation of results 
The analyst, when examining an assay for prospective use, is interested 
in 4 parameters: accuracy, reproducibility, sensitivity and specificity. 
15 
In this thesis, accuracy and reproducibility have been determined by 
the repeated assay of samples spiked with several known amounts of 
prizidilol so that peak heights of the added internal standard and 
those corresponding to different concentrations of prizidilol were 
obtained. The peak height ratios (prizidilol/internal standard) were 
calculated and calibration curves were obtained. From these the 
recovered concentrations could be calculated and compared to the known 
(because added) concentrations in the samples analysed. From these 
data, it would, when necessary, be possible to estimate how accurate 
a concentration estimate would be, were a sample containing an unknown 
amount of drug to be analysed. This point needs to be emphasised 
since, if a calibration curve is linear (as in the HPLC methods 
discussed in this thesis) the same parameters for coefficients of 
correlation and variance will be obtained if the peak height ratios 
are used instead of the recovered concentrations; but, if the calibr-
ation curve is not linear (as in the TLC method), this is not the 
case. 
The sensitivity (or limit of detection) was calculated for each assay 
method semiempirically. The extreme scatter due to baseline "noise" 
was determined experimentally in blanks at the positions where 
prizidilol would be expected to appear then, knowing the heights of 
the internal standard peaks and using the calibration curves, it was 
possible to calculate the concentration of prizidilol in samples 
which would give rise to peaks twice as high as the baseline scatter 
for the method employed. The estimates derived would be different 
from those made using variances calculated during regression analysis 
but they are probably of more practical utility, especially when a 
nonlinear calibration curve is encountered or a linear curve for 
which the conventionally-used linear regression is, strictly speaking, 
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invalid because of inhomogeneity of variance. 
The specificity was not examined because tbe p
resence of interfering 
drugs was not anticipated, the assays were vali
dated using pooled 
human serum samples and the chromatographic na
ture of the assays 
makes it unlikely that interfering drugs or end
ogenous substances 
reacting with quinolin-3-al would cause problem
s. However, had 
the drug been assayed in subjects participatin
g in pharmacokinetic 
trials, the matter would have been pursued furt
her, but prizidilol 
was withdrawn from clinical testing before this
 stage was reached. 
2.2.2 SK & F method (81) 
2.2.2.1 Materials and equipment 
2.2.2.l.1 For derivatization and extraction 
Trichloroacetic acid (5% w/v aqueous solution) 
reagent grade 
Anisaldehyde (1% v/v methanolic solution); a fr
esh solution 
was prepared on each day of analysis 
Sodium hydroxide solution (4M) 
Dichloromethane (HPLC grade) 
Methanol (HPLC grade} 
Glass distilled water 
12 ml polypropylene tubes and stoppers 
15 ml glass culture tubes with screw cap 
Blood cell suspension mixer 
Vortex mixer 
Vortex evaporator was set at 25° and 375 mm Hg 
with cold trap 
containing propan-2-ol and solid co2 
Centrifuge 
Shaking water-bath was set at 10°c 
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2.2.2.l.2 For high performance liquid chromatography (HPLC) 
a) Solvent system: 
b) Instrumentation: 









Waters 6000A or equivalent 
Perkin Elmer LC-75 or equivalent 
Waters WISP, Rheodyne 7125 or 
equivalent 
Zorbax-CN 5 µm packed in a 
stainless steel column 150 mm 
X 4.6 mm i.d. 
Integrator: Perkin Elmer Sigma 10 or 
equivalent. 
Prizidilol dihydrochloride (SK&F 92657-A2) 2.55 mg (= 2.0 mg 
base) 
dissolved in 200 ml of methanol. 
SK&F 93238 trihydrochloride (SK&F 93238-A3) 5.44 mg (= 4.0 mg bas
e) 
dissolved in 200 ml of methanol. 
Fresh solutions were prepared on each day of analysis. 
2.2.2.2 Methods 
2.2.2.2.l Extraction and derivatization procedure 
1. l ml of plasma was measured (by pipette) into a 12 ml 
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polypropylene tube, to which was added 100 µl of the internal 
standard solution (equivalent to 2 µg SK&F 93238) and mixed 
by vortex. The sample was allowed to stand for 5 minutes at 
room temperature. 
2. To this was added 2 ml trichloroacetic acid (5% w/v aqueous 
solution) which was mixed by vortex and centrifuged for 
5 minutes at 2500 rpm. 
3. The supernatant was poured off into a 15 ml screw-cap glass 
tube, and 100 µl anisaldehyde solution (1% v/v in methanol) 
was added. This was then incubated in a shaking water-bath 
maintained at 70°c for one hour. 
4. The tubes were cooled to room temperature and the pH then 
adjusted to 12 with ca. 200 µl of 4 M sodium hydroxide solution. 
5. 4 ml dichloromethane was added and rotated on a blood cell 
suspension mixer for 10 minutes. The sample was centrifuged 
for 5 minutes at 1500 rpm, and the aqueous layer aspirated 
and discarded. 
6. The organic layer was transferred to a 12 ml polypropylene 
tube and evaporated to dryness in a vortex evaporator for one 
hour at 25°c. 
7. The residue was reconstituted in 100 µl methanol/water/glacial 
acetic acid (75: 25: 0.1). At this stage the samples could 
be stored overnight at -20°c. 
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2.2.2.2.2 Preparation of HPLC solvent 
All solvents were filtered through 0.5 µm Millipore filters prior 
to mixing. 
375 ml methanol and 125 ml distilled water were mixed and degassed 
under reduced pressure. 0.32 ml n-dibutylamine and 0.14 ml 









Methanol/water (75 25), 0.004 M dibutylamine 





The column was allowed to equilibrate with the solvent for at 
least 2 hours. After use, the column was flushed with methanol/ 
water (75: 25) for a minimum of one hour. 
2.2.2.2.4 Chromatography 
5 - 20 µl aliquots of the extracts were injected to obtain the 
chromatogram (see Fig. 6). 
Retention times for prizidilol hydrazone and SK&F 93238 hydrazone 
were ca. 7 minutes and 8 minutes respectively. 
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Fig. 6 SK & F method: typical HPLC chromatograms 




12 9 6 3 0 
Retention time (minutes) 
12 9 6 3 0 
Retention time (minutes) 
A) Control serum sample spiked with internal standard 
8) Serum sample containing prizidilol (0.50 mg/1 ) and internal standard 
1. Anisaldehyde · 
2. Prizidilol anisaldehyde hydrazone 
3. SK & F 93238 anisaldehyde hydrazone 
arrow denotes the time injection. 
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2.2.2.2.5 Standard curve 
1. Tubes (where appropriate, in replicate) were labelled SlOOO, 
S800, S600, S400, S200, SlOO, S50, and B. 
2. Into tubes SlOOO were put 100 µl standard solution; into 
S800, 80 µl; into S600, 60 µl; into S400, 40 µl; into S200, 
20 µl; into SlOO, 10 µl; S50, 5 µl and into B zero. 
3. The methanol was evaporated off using the rotary evaporator. 
4. Just before analysis 1 ml serum was added to each tube and 
mixed. 
5. This made standards at each of the following concentrations 
of prizidilol base; 1 µg/ml (Sl 000), 800 ng/ml (S800), 
600 ng/ml (S600}, 400 ng/ml (S400), 200 ng/ml (S200), 100 ng/ml 
(Sl 00), 50 ng/ml (S50) and zero (B). 
6. Standards were worked up according to section 2.2.2.2.1 
"Extraction and derivatization procedure" steps 2 to 7. 
2.2.2.3 Validation of the method 
The procedure was followed as exactly as possible and a calibration 
curve was obtained by plotting peak height ratios against concentr-
ation of samples spiked with known amounts of prizidilol and internal 
standard. The data obtained are presented in Table 1. The calibration 
curve was linear in the range 0.05 - 1 mg/1 (Fig. 7). 
Plot of peak height ratio (prizidilol/internal standard) against 
spiked prizidilol concentration (Fig. 7): Slope= 3.58 (SD= 0.06}; 
y-intercept = 0.04 (SD= 0.04); r = 0.9960. 
Plot of recovered against spiked prizidilol concentrations: 
Slope= 1.00 (SD= 0.02}; y-intercept = 0.00 (SD= 0.01); r = 0.9960. 
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Spiked Peak height Recovered 
cone. (mg/1) ratio Mean cones. (mg/1) Mean CV (%) 
0.05 0.28 0.237 0.068 0.056 34 
0.25 0.070 
0.18 0.035 
o. 1 0.41 0.367 0.105 0.092 14 
0.35 0.088 
0.34 0.085 
0.2 0.69 0.723 0.183 0.193 8 
0.70 o. 186 
0.80 0.214 
0.72 0.191 

















Table l. Validation of SK & F standard assay (81): replicate determinations 
of prizidilol in spiked human serum. 































































































































































































































Overall CV= 11%. 
(SD= standard deviation: r = correlation coefficient; 
CV= coefficient 
of variation). 
Minimum detectable concentration was about 50 µg/1. 
2.2.3 New extraction of prizidilol, for both HPLC and 
TLC assays 
2.2.3.l Materials and equipment 
10 ml glass tubes with liquid-tight closures 
Pipettes and micropipettes 
Volumetric flasks 
A rotary evaporator with bath set at 25°c for evaporati
on of 
methanol solution was used 




Water bath at 45-47°C 
Distilled water 
Human serum 
Methanol (HPLC grade) 
Dichloromethane 
Propan-2-ol 
85% orthophosphoric acid (20% v/v aqueous solution) 
Sodium hydroxide solution (3.5 M) 
Quinolin-3-al (2% w/v propan-2-ol solution) 
Pepsin: EC 3.4.2.3.l from porcine stomach mucosa, crys
tallised 
and lyophilised 3000 units/mg 
(2% w/v aqueous solution) 
N.B. All glassware coming in contact with samples conta
ining prizidilol 
and/or the internal standard was silanised. 
2.2.3.2 Standard solutions 
Prizidilol stock solution: 2.55 mg prizidilol dihydroc
hloride 
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hydrate(= 2.0 mg base) dissolved in 200 ml methanol (10 µg/ml). 
Internal standard solution: 1.36 mg SK&F 93238-A3 4-(prop-l-oxy) 
prizidilol trihydrochloride (= 1.0 mg base) dissolved in 50 ml 
methanol (= 20 µg/ml). 
2.2.3.3 Extraction procedure 
l. Pooled human serum was spiked to give samples containing various 
concentrations of prizidilol (see Tables 2, 3 and 4). Blanks were 
also analysed, but no interfering peaks were observed. Replicate 
analyses were performed on each sample. 
2. To each l ml spiked serum (or blank) was added, with mixing, a 
reproducible volume (about 25 µl) of internal standard solution, 
then, 
3. with mixing between each step, were added 100 µl phosphoric acid, 
100 µl pepsin and 20 µl quinolin-3-al solutions. 
4. Each tube was heated at 45° for 45 min, before cooling to below 25°. 
5. To each reaction mixture, with mixing, was added 250 µl sodium 
hydroxide solution, then" 
6. 6 ml dichloromethane as soon as was practicable. 
7. Each tube was inverted about once a second for 15 min. 
8. Phases were separated by centrifugation at about 2500 g and each 
organic layer collected into a clean, appropriately-labelled tube 
by filtration through a cotton-wool plug s·oaked in dichloromethane. 
9. The organic filtrate was evaporated to dryness under nitrogen at 
about 25°. 
10. The dried extracts were stored, when necessary, at -20° in the dark. 
- ---------~ 
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2.2.4 New HPLC assay 
2.2.4.1 Materials and equipment 
Spectraphysics model 3500 high-pressure liquid chromatograph fitted 
with a model 770 spectrophotometric detector and Phillips PM8100 
recorder. Samples were injected into a 10 µl loop injector using 
a Glenco gas syringe. 
Reversed phase column used was 30 cm x 3.9 nm i.d. 5 micron Bondapak 
Cl8 from Waters Associates. (The mode of reversed-phase chromato-
graphy utilizes, in this case, hydrophobic octadecyl residues bonded 
to silica as stationary phase and a polar mobile phase; the less 
polar the solute, the more it binds hydrophobically to the stationary 
phase and therefore the greater its retention). 
Methanol 
Di sti 11 ed water 
Tri ethyl amine 
Orthophosphoric acid (85%) 
Mobile phase: Filtered and degassed mixture of 590 ml water, 750 ml 
methanol, 800 µl triethylamine and enough phosphoric acid (about 400 
µl) to bring the pH to 4.7. 
2.2.4.2 Operating conditions 
Detection wavelength: 334 nm (see Fig. 8) 
Sensitivity: range 0.01 AUFS, recorder input 1 mV 
Recorder chart speed: 5 mm/min 
Flow rate: 1.6 ml/min 
Pressure about 250 p.s.i. indicated 
















300 320 340 360 380 4
00 
Wavelength, nm 
Key: • • 8-+--
prizidilol (SK & F 92657) 
internal standard (SK & F 93238) 
Absorption spectra of derivatised prizidilol and 
internal standard in mobile phase. 
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2.2.4.3 Analysis 
Each dried extract (section 2.2.3.3.10) was redissolved in 50 µl 
mobile phase. 
10 µl portions were injected to obtain chromatograms (Figs. 9 and 10). 
Retention times were about 5 min for the prizidilol hydrazone and 
r5 min for the internal standard hydrazone. 
The wavelength used was chosen empirically to minimise interference 
from other compounds in the extract. 
2.2.4.4 Validation of the method 
A calibration curve was obtained (Fig. 11) by plotting peak height 
ratio (prizidilol/internal standard) against concentrations of samples 
spiked with known amounts of prizidilol and internal standard. The 
data obtained are presented in Table 2. The calibration curve was 
linear in the range 0.05 - l mg/1. 
Plot of peak height ratios against concentration: 
Slope= 3.54 (SD= 0.04); y-intercept = 0.05 (SD= 0.02); r = 0.9984. 
Plot of recovered against spiked prizidilol concentrations: 
Slope= 1.00 (SD= 0.01); y-intercept = 0.00 (SD= 0.01); r = 0.9984 
Overall CV= 9%. 
(SD= standard deviation; r = correlation coefficient; CV= coefficient 
of variation). 
Minimum detectable concentration about 30 µg/1. 
2.2.4.5 Corm1ents 
Although the coefficients of variation and correlation were seemingly 
improved for this HPLC method over the standard HPLC technique, and 
the minimum detectable limit was lower, both methods were disappointingly 
" 29 












18 15 12 9 6 3 0 18 15 12 9 6 3 0 
Retention time (minutes) Retention 
time (minutes) 
A) Serum sample containing prizidilol 
B) Serum sample containing prizidilol and internal standard 
1. quinolin-3-al 
2. SK & F 93238 quinolin-3-al-hydrazone 
3. prizidilol quinolin-3-al-hydrazone 
The-arrow denotes the time injection. 
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Fig. 10 The HPLC method: typical chromatograms 
A) 1 B) l 
2 
l 
15 12 9 6 3 0 15 12 9 6 3 0 
Retention time (minutes) Retention time (minutes) 
A) Control serum 
B) Serum sample spiked with internal standard 
1. quinolin-3-al 
2. SK & F 93238 quinolin-3-al hydrazone 





































































































































































































































Spiked Peak height Recovered 
cone. (mg/ l ) ratio Mean cone. (mg/1) 
Mean CV (%) 




































3.64 1. 014 
Table 2. Validation of new HPLC assay: replicate detenninations of prizidil
ol 
in spiked human serum. 
CV= coefficient of variation; cone.= concentration. 
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slow to perform and column cleaning procedures were too ofte
n 
necessary. 
2.2.5 TLC assay 
2.2.5.l Materials and equipment 
2.2.5.1.l a) Materials 
Disposable 5 µl micropipettes for TLC sample application; 
Drummond microcaps used. 
Hairdrier; any source of cool air {below 30°C). 
Vacuum dessicator; needed to be large enough to hold at leas
t 
one 10 x 20 cm TLC plate. 
Water pump; to deliver a vacuum of about 15 torr when connec
ted 
to the vacuum dessicator. 
Tank for TLC elution; needed to be large enough to hold at l
east 
one 10 x 20 cm TLC plate. 
Glass rod with round end; the diameter of the rod should be 
at 
least a third of that of the glass tubes. 
Funnels should have a volume of about 10 ml. 
Cotton wool. 
Silica plate for TLC, 10 cm x 20 cm, Merck HPTLC-precoated 






An111onia solution (25% in water; S.G. = 0.9) 
All analytical grade or purer. 
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c} Instrumentation: 
A Zeiss KM3 Chromatogram spectrophotometer was used to measure 
the fluorescence of the spots on the thin-layer plates. The 
following operating conditions were used: 
l. Indicator unit 
Model selector set to 11 R11 
Recording mode selector to KOMP A 
Damping switch set to 11 111 
High voltage selector to step l 
2. Recorder unit 
Chart paper speed 5 cm/min. 
Scanning speed 120 mm/min. 
Measuring range 500 mV 
3. Il luminator and monochromator 
Mercury source was provided 
Exciting wavelength set to 366 nm 
Slit width set to 0.04 mm 
Blank barrier filter was used 
Slip-in diaphragm 3.5 mm was used 
The amplification was adjusted to obtain approximately 
95% full-scale deflection on the recorder when the 
blank spot in the chromatogram was being scanned. 
2.2.5.l.2 Standard solutions 
Tubes (where appropriate, in replicate} were labelled SlOOO, 
S750, S500, S250, SlOO, S50, B, into tubes SlOOO put 100 µl 
11stock 11 , 
into S750, 75 µl; into S500, 50 µl; into S250, 25 µl; into SlOO, 
10 µl; into S50, 5 µl; and into B zero. 
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The solvent was evaporated off by using the rotary evaporator 
and the residue then re-dissolved in l ml serum to each tube 
and mixed. This makes two standards at each of the following 
concentrations of prizidilol base: l mg/1 (S1000), 750 µg/1 
(S750), 500 µg/1 (S500), 250 µg/1 (S250), 100 µg/1 (SlOO), 
50 µg/1 (S50) and zero (B). 
2.2.5.1.3 Operating solutions 
"Spotting solvent": 500 µl acetic acid mixed with 500 µl butan-
2-one. 
"Chromatographic solvent": 15 ml acetone+ 5 ml butan-2-one 
+ l ml ammonia solution. 
"Washing solvent": 20 ml acetone + 200 µ l acetic acid. 
The latter three solvent mixtures were constituted just before 
use. 
2.2.5.2 Analysis 
l. Each dried extract (section 2.2.3.3. 10) was dissolved in 10 µl 
"spotting solvent" by smearing this over the inside of the tube 
using the glass rod. 
2. The solution was drained to the bottom of the tube by brief 
centrifugation. 
3. The rod was rinsed with ethanol and dried between samples. 
4. Each silica TLC plate was marked lightly in pencil with a line 
drawn l cm from an edge arbitrarily assigned as the bottom of the 
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plate. The line (the origin) was then subd
ivided at 1 an intervals 
and each subdivision labelled lightly to ide
ntify the sample to be 
applied there. 
5. For each sample, a 5 µl aliquot was appli
ed to the appropriately-
labelled position. 
6. The spots were dried using cool air from 
a hairdrier, 
7. then developed to the top of the plate (9
 cm distance) with the 
"washing solvent". 
8. The plate was then dried in vacuo (about 
20 Torr) for not less than 
15 min. 
9. Meanwhile, the freshly-constituted 
11 chromatographi c sol vent" was 
put into the chromatography tank and allowed
 to equilibrate with 
the atmosphere therein, a process aided by o
ccasional vigorous 
shaking. 
10. The plate was then developed to the top 
immediately after removal 
from the dessicator. 
11. The plate was again dried using cool air
 from the hairdrier posi-
tioned at least 60 cm from the plate. 
12. Using the mercury arc lamp of the densit
ometer, selecting a scanning 
wavelength of 366 nm and with the instrumen
t in absorption mode, 
the instrument zero was set while illuminati
ng a clean portion of 
plate. Recorder full-scale deflection was t
hen set while scanning 
a spot corresponding to the highest prizidil
ol concentration antici-
pated. 
13. Typical chromatograms are shown in Fig. 
12. 
14. Each sample development track in turn w
as scanned and the peak 
heights corresponding to prizidilol and the 
internal standard were 
measured. 
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2.2.5.3 Validation of the assay 
Calibration curves were obtained {Figs. 13 and 
14) by plotting peak 
height ratios (prizidilol/internal standard) a
gainst concentration 
of samples spiked with known amounts of prizid
ilol and internal standard 
(500 ng for data in Fig. 13 and Table 3; 550 ng
 for data in Fig. 14 and 
Table 4). Note that neither calibration curve
 is linear; this is 
normal for TLC absorptiometry. 
Plots of peak height ratio (y) against concent
ration (x) 
Figure 13 and Table 3: 
y = 1.43 {l - e-l. 5Sx) 
Figure 14 and Table 4: 
y = 1.54 (l - e-1.32X) 
Plots of recovered against spiked prizidilol c
oncentrations: 
Fig. 13 and Table 3: 
Slope= 1.01 (SD= 0.01); y-intercept = 0.00 {
SD= 0.01); r = 0.9979 
Overall CV= 6%. 
Fig. 14 and Table 4: 
Slope= 1.00 (SD= 0.02); y-intercept = 0.00 (
SD= 0.01); r = 0.9963 
Overall CV= 8%. 
(SD= standard deviation; r = correlation coef
ficient; CV= coefficient 
of variation) 
Minimum detectable concentration about 15 µg/1
. 
2.2.5.4 Comments 
As might be expected when the calibration curve
 is (nearly) a rising 
exponential, the precision of the TLC assay is
 not superior to that of 
the HPLC assay at high concentrations, but com
parison of the results 
shown in Tables 3 and 4 with those in Tables l 
and 2 show a definite 
advantage for the former method at low concen
trations. This observation 
has one obvious consequence, that if a sample 







































































































































































































































































Spiked Peak height 
Recovered Mean 
cone. (mg/1) ratio Mean 
cone. (mg/1) (SD) CV (%) 
0.05 0.16 0.157 






0.1 0.26 0.269 





0.25 0.55 0.544 0.265 
0.263 6 
0.53 0.257 (0.016) 




0.5 0.85 0.829 0.514 
0.491 5 





0.75 1.04 1.038 0.728 
0.733 5 





1 1.22 1.204 1.053 1.
023 4 
1.19 0.985 (0.037) 
1.19 0.997 
1.21 1 .026 
1.21 1.035 
1.21 1.044 
Table 3. Validation of new TLC assay: replicate determin
ations of prizidilol 
in sp.i ked human plasma. 

























































































































































































































































































Spiked Peak height Recovered Mean 
cone. (mg/1) ratio Mean cone. (mg/1) (SD) CV (%) 




0.1 0.22 0.218 0.106 0.105 8 
o. 21 0.098 
0.23 0.110 
0.22 0.107 
0.25 0.48 0.269 0.241 9 
0.42 0.438 0.231 
0.41 0.225 
0.44 0.241 




0.75 0.95 0. 700 0.724 5 
0.99 0.967 0.752 
0.99 0. 749 
0.94 0.696 
l 1.18 l.165 1 .054 l. 015 5 
1.11 0.940 
Ll6 1. 029 
1.17 l. 036 
3.bl e 4. Validation of new TLC assay: replicate determination of 
prizidilol in spiked human plasma 
CV= coefficient ot variation; cone.= concentration. 
....... 
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to be likely to contain more than, say, 800 µg/1 prizidilol, it is 
advisable to apply to the TLC plates more dilute solutions of standards 
and unknowns than is indicated in section 2.2.5.2.l • It is also 
clear that extrapolation would be particularly hazardous. 
A curiosity of the statistics is that, while the coefficients of 
variation for the TLC assay were generally similar to or lower than 
those for the HPLC assay, the correlation coefficients were not better. 
Examination of the data, however, suggests that this may be because, 
in the former assay, the variances were not homogeneous throughout 
the concentration range so that to apply the standard linear regression 
equations is incorrect, strictly speaking, and will lead to a pessimistic 
estimate for r. 
The TLC method was adopted for the studies on drug metabolism because, 
although the procedures (section 2.2.5.2) are relatively lengthy, up 
to 19 samples could be washed and eluted simultaneously. The advantages 
suggested for TLC in section 2.1.3 (last paragraph) were justified in 
practice. 
2.5.5 Extraction efficiency 
Samples were prepared containing 1 mg/1 or 0.5 mg/1 prizidilol in 
serum and were analysed as described in sections 2.2.3.3 and 2.2.5.2. 
The results are presented in Tables 5 and 6. The extraction efficiency 
from plasma was about 97% which suggests that any protein binding effect 










Peak height of 













0. 113 ± 0. 007 
0. 111 6. 2~; 
0.114 
0.220 
0.206 0. 218 ± 0 . 009 
0. 1 0.227 0.238 4. 1 ;; 
0.222 
0.479 
0.423 0.438 ± 0.028 










0.950 2. 5~~ 
0.944 
1 . 176 
1.114 1 . 155 ± 0. 028 
1. 0 1. 224 1 . 163 2. 4 :s 
1 . 167 
Table 4 Data from calibration curve for the validation of TLC method 
for prizidilol in serum. 
y = l . 1 Ox + 0. l 3 




















































































































































































































































































































































































































3. METABOLISM OF PROPRANOLOL, HYDRALAZINE AND PRIZIDILOL 
Prizidi1o1 is a molecular moiety representing a combination of proprano1o1 
and hydralazine. In this chapter the metabolism of proprano1o1 and of 
hydralazine, and the pharmacokineticsof prizidilol itself - as far as 
they are known - are reviewed. 
3.1 Metabolism of propranolol 
Proprano1o1 is virtually completely absorbed after oral administration (86). 
Peak plasma concentrations of propranolol are seen at approximately 2 hours 
(range 1 to 4 hours) in fasting patients (87-90). Administration of food 
does not significantly change the time for achievement of peak levels 
in healthy individuals given a single tablet of propranolo1 with a 
standardised meal, though systemic availability of the drug was increased 
by feeding (91). There appears to be no relationship between the half-life 
of gastric emptying and the time at which peak plasma proprano1o1 con-
centration is attained (92). 
Propranolol is widely distributed through body tissues after administration. 
The apparent volume of distribution derived from the s portion of the 
concentration time curve (Vds) is approximately 200 litres (93, 94). This 
exceeds the physiological body space and it indicates that propranolol 
is concentrated in extravascular sites (94). This proposal is supported 
by experimental data in animals showing high concentrations of propranolol 
in lung, liver, kidney, brain and heart after oral and intravenous adminis-
tration of propranolol (95, 96). 
Propranolol is extensively bound (85 to 96:~) to protein in plasma in man 
(97-99). Since only 62% is bound to human serum albumin (5 g/100 ml), 
other proteins are also important in determining the degree of binding of 
this drug (97). Propranolol is bound to lipoproteins independent of serum 
propranolol concentration, and also to a 1 acid glycoprotein. The latter 
protein is reported to be responsible for 75t of binding of propranolol to 
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plasma proteins at therapeutic propranolol concentrations (98). Red 
blood cells also bind significant quantities of the drug (99). Red cells 
have been shown to partition about 5:1 with free drug in plasma (100). 
Blood/plasma ratios of approximately 0.85 have been found in monkey, dog 
and rat. In man, values between 0.85 and 1.5 have been reported (101, 102). 
Propranolol is almost entirely eliminated following metabolism by various 
enzyme systems in the liver (103). The systemic clearance after intra-
venous administration was about l litre/min with values varying from 
0.6 to 1.5 litre/min (89, 94, 104, 105). The plasma elimination half-
life was between 2 and 3 hours but values of 4 hours have been reported 
(89, 104). 
Shand et~ have shown that drug concentrations declined biexponentially 
after intravenous administration in man. The early a-phase had a half-life 
of 10 minutes and the later s-phase of 2.3 hours (94). 
curve has also been observed in rat (106). 
A biphasic 
Early studies of healthy young volunteers established that propranolol 
was eliminated almost entirely as metabolites. Only l to 4% of a 
radiolabelled dose was recovered as the parent drug in the urine and faeces 
(86). In 1976, Bond characterized the metabolites of propranolol as 
acidic (30%) and amphoteric (70%), with only minute amounts of basic 
products. Bond isolated two of the main metabolites, 4-hydroxy propranolol 
and propranolol glucuronide (107). Since that early report, at least 
19 metabolites have been identified (108-110). 
The documented pathways for the metabolism of propranolol are shown in 
Fig. 15. The four primary pathways involve 0-dealkylation, side chain 
oxidation, glucuronic acid conjugation and ring oxidation. The metabolic 
degradation of propranolol in man involves first, oxidative deamination 


































l oxidative decarboxylation 
(VI) 
Schematic representation of propranolol metabolism in man 
and dog. I, propranolol; II, desisopropylpropranolol; 
III, proposed aldehyde; IV, glycol; V, naphthoxylactic acid; 
VI, naphthoxyacetic acid; VII, OH-glycol; VIII, 4-hydroxy-
propranolol; IX, a-naphthol; X, dihydroxynaphthalene; 
~I, isopropylamine 
LBased on Walle and Gaffney (116) ] 
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naphthoxylactic acid (V) by aldehyde dehydrogenase or to propranolol 
glycol by an aldehyde reductase. Small amounts of naphthoxyacetic acid 
(VI) are formed from naphthoxylactic acid (V). Ring hydroxylation of 
propranolol (I) in the 4-position, gives rise to 4-hydroxypropranolol 
(VIII) and also to the 4-hydroxypropranolol glycol (VII). In addition, 
significant quantities of a-naphthol (IX) and dihydroxynaphthalene (X) 
are formed as well as methoxy metabolites, these latter suggesting that 
propranolol passes through the catechol-0-methyl transferase pathway 
(111). Most of these metabolites are subsequently conjugated and excreted 
as glucuronide or sulfate conjugates. The 4-hydroxy metabolite of 
propranolol (VIII) which is formed only after oral administration of 
propranolol has equivalents-antagonist activity to propranolol (86,112). 
The isopropylamine metabolite (XI) has sympathomimetic activity, and 
it has been speculated that the glycol metabolite (IV) may contribute 
to propranolol 's effects on the central nervous system (113,114). 
Propranolol has varied pharmacological effects, and it is possible that 
several of the metabolites contribute to these properties (115); 
4-hydroxypropranolol (VIII), which can be a major metabolite depending 
on route of administration of propranolol (112), as mentioned above, 
exhibits s-antagonistic activity. Hayes and Cooper ( 95) and others 
(116) detected 4-hydroxypropranolol only after oral dosing; they 
proposed that hydroxylation occurs only when the concentration of 
propranolol in the portal vein exceeds that necessary to saturate the 
other metabolic pathways. 
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3.2 Metabolism of hydralazine 
Hydralazine is well absorbed from the gastrointestinal tract, 
approximately 87~ of circulating hydralazine being bound to plasma 
protein (117). Peak plasma concentrations occur after three 
to four hours oral administration (118). 
This drug appears to be rapidly and extensively metabolized (84). 
About 90% of the absorbed hydralazine is excreted in urine. Less than 
5% of the parent drug is eliminated unchanged (53). After ingestion, 
considerable gut wall and first pass liver metabolism occurs to produce 
a phthalazine derivative (II) (117, 119). The pathways for the metabolism 
of hydralazine are shown in Fig. 16. The major metabolites are products 
of acetylation, hydroxylation and conjugation reaction (17, 120). 
For the most part, the acetylated product (Acetyl HP, VIII) undergoes 
cyclization to form a triazolophthalazine (TP, IV) derivative. TP is 
devoid of any antihypertensive activity (121). In man, TP, PZ (III), 
HTP (VI) and HTP glucuronide have been identified in the urine of 
patients given hydralazine (122). The triazolo metabolites of hydrala-
zine (TP, MTP (IV) and HTP) are separable by gas and high performance 
liquid chromatography (123, 124); PYR (VIII) has been shown to be a 
conjugate of hydralazine with pyruvate (125). In the urine of rats 
administered 14c-hydralazine hydrochloride HP-glucuronide or the 
glucuronide of 7-hydroxy-hydralazine, N-acetyl HP, hydroxy HP and PYR 
have been identified. The major metabolite in rats is 3-methyl-5-triazolo 
(3,4a) phthalazine (MTP) (124, 125). 
HO-NHNHz + [ ~l l 
hydroxyhydraz i ne P I I '( 
CH3 
NHN - C~ 
COOH 
AfJJ ~;;. ~ sat,on 





"ACETYL HP" VIII 
N-N 
ld acetyl~ilin l cyclization 
OOt OCt ~'", 
HP I MTP V 















Fig. 16 Metabolism of hydralazine. Compounds in brackets have not been 
isolated as metabolites. Dotted lines represent suggested pathways. co2 
was formed in vivo from (methyl- 14 CJ -MTP. a: HTP may also be formed 
directly by reaction of HP with glycolic acid. b: HP may also be formed 
by reaction with formic acid. c: HP may also form hydrazones with other 
endogenous carbonyl containing compounds such as pyridoxal, glucose, ascor-
bic acid, and macromolecules. The hydrazones can be hydrolyzed. d: PZ 
(which can exist as tautomers) may be formed nonenzymatically (e.g., 
via paroxidation). P may also be formed nonenzymatically. In these cases 
the nature of the eleaved N-N product is not known. 
I HP: Hydralazine 
II P: phthalazine 
III PZ: phthalazinone 
IV TP: s-triazolo (3,4-aJ phthalazine 
V MTP: s-methyl-s-triazolo (3,4-a: phthalaz 
VI HTP: 3-hydroxy-methyl-s-triazolo ~3,4-a 
VII PYR: pyruvic acid hydrazone 
VIII Acetyl HP: acetylated hydralazine. 




In comparison to normal patients, "fast acetylators 11 exhibit 
smaller plasma concentration-time curves for hydralazine and less 
incidence of lupus (viz. the development of antinuclear antibodies). 
"Fast acetylators" thus require more hydralazine for adequate blood 
pressure control (126). 
3.3 Metabolism of prizidilol 
The concentration of prizidilol in the plasma of rats and baboons 
has been estimated after oral administration of the compound. At the 
time of maximum plasma concentration (2 to 3 hours after oral dosing) 
direct proportionality between dose and plasma concentration is seen 
in baboons but not in rats (127). 
Studies of the metabolism of 14c-prizidi1o1 support the existence of 
a first pass effect for this compound in rats, since 89% of an oral 
dose was excreted in the faeces, whereas only 48% of an IV dose was 
excreted by this route during the 24 hours after dosing. No barrier 
to absorption was observed in rats even at the highest dose which 
produced individual plasma concentrations as high as 55 mg/1 (127). 
Whole body autoradiography of rats indicated that, 30 minutes after a 
dose of 14c-prizidilol, radioactivity was found mainly in the liver 
and kidney and in tissues containing collagen and elastin such as the 
cartilage of the ear and aortic wall (Table 7). At no time was measurable 
radioactivity 0etected in the brain after administration of 14c-prizi-
dilol (127) (Table 7). 
The urinary metabolites of 14c-prizidilol have been examined in rats, 
cats and baboons. In rat urine, the parent compound and four 
































































































































































































































































































































































































































































































































































































































































































































observed up to five hours after dosing. Preliminary results from 
the cat and baboon suggest a similar pattern of urinary metabolites, 
but without better chemical characterisation than Rf values, it is not 
possible to state that these three species metabolize prizidilol in 
a similar manner (127). 
Collection of urine and faeces, and biliary cannulation in rats dosed 
with prizidilol has indicated that both the kidney and 
in eliminating the parent drug and/or its metabolites. 
liver play a role 
14 No co2 was 
found in expired air, suggesting that 
14c-prizidilol does not contribute 
labelled co2 to the metab
olic pool (127). 
A bolus injection of 20 mg/kg IV prizidilol had no effect on any of the 
biochemical assays for liver function, including alanine and aspartate 
aminotransferases unless the concentration of prizidilol in the blood 
approached 250 µM. Such a high concentration of the parent drug is 
not approached following IV infusion or oral administration of 
approximately 10 mg prizidilol base to a human subject. Therefore, 
at the doses likely to be given to human subjects, it appears that 
aminotransferase and other liver function tests are not affected. 
Male rats, starved overnight, received 900 mg/kg prizidilol in an 
attempt to effect liver aminotransferase activity. Liver samples were 
taken between two and three and a half hours after dosing, to correspond 
with the maximum blood concentration of prizidilol. In these experiments, 
the hepatic aminotransferase activity control and treated rats did not 
differ significantly (127). 
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4. HEPATIC DRUG METABOLIZING ENZYMES 
The aim of this portion of my thesis was to investigate aspects of the 
hepatic metabolism of prizidilol. In particular, the metabolism of this 
drug by three liver enzyme systems which are known to interact with 
xenobiotics was investigated. The enzyme systems which were studied 
were the cytochrome P-450 enzyme system (128, 129), the glutathione-S-
transferases (130, 131) and the acetyltransferases (132, 133). 
4.1 General introduction on drug metabolism 
Drug metabolism is the process whereby a wide range of xenobiotics, viz., 
drugs, carcinogens and environmental pollutants, undergo enzymatic 
biotransformation leading to the production of a variety of metabolites. 
In mammals, the metabolic transformation of these compounds occurs 
primarily in the liver, although most organs and tissues have some 
capability for xenobiotic transformation. The enzymes involved in the 
metabolism of xenobiotics are known as drug metabolizing enzymes. 
Drug metabolism is considered to occur in two distinct stages. The two 
phases of drug metabolism are shown in Fig. 17. The enzymes catalyzing 
Phase I and Phase II reactions are summarized in Table 8. 
Fig. 17 The general pathway for the metabolism of xenobiotics. 
XENOBIOTIC (Insoluble in H20, Toxic) 
Oxidation 1 Phase I 
OXIDIZED (OR HYDROXYLATED) (Slightly soluble) 
XENOBIOTI C 
Conjugation I Phase II .., 
CONJUGATED XENOBIOTIC (Very soluble, not toxic) 
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Table 8 : Hepatic metabolism of xenobiotics (134-136). 
Reaction Enzyme 
Major subcellular 
location of enzyme 
Phase I 
I 
Oxidation of aliphatic Cytochrome P-450 Endoplasmic 
I and aromatic groups, 
reticulum, nuclear 
N-oxidation, sulphoxida- envelope 
tion, oxidative dealkyla- I I 
tion, epoxidation I 
I 
Reduction of azonitro- Flavin enzymes Endoplasmic I 
compounds or cytochrome reticulum I P-450 
Reduction of carbonyl- Cytochrome P-450 Endoplasmic I I 
compounds and halo- reticulum, nuclear 
compounds envelope 
Oxidation and reduction A le oho 1 dehydro- Cytosol and various 
of alcohols, aldehydes genase, aldehyde organelles ' I I 
and carboxylic acids dehydrogenase 
Oxidation of amines e.g. Monoamine Mitochondria 
ox1dases 
Hydrolysis of esters 
I 





Conjugation with UDP-glucuronyl Endoplasmic 
l 
I 
glucuronic acid transferases reticulum, nuclear 
envelope 
Conjugation with Glutathione-S- Cytosol, Endoplasmic 
glutathione transferases reticulum 
Conjugation via Acetyl trans fe- Cytoso 1 
acetylation rases 
Conjugation with sulphate, Various transfe- Cytosol and various 
I glycine, other amino acids; rases organelles and methylation 
Hydration of epoxides Epoxide hydrase Cytosol and Endo-
plasmic reticulum 
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Phase I involves the oxidative conversion of the lipophilic or fat-
soluble compound into more hydrophilic or water soluble products by reactions 
such as dealkylation, deamination and hydroxylation. Phase II involves 
the conjugation of the oxidized intermediate or the parent compound 
with a small, polar organic molecule such as glutathione, glucuronic 
acid or sulfate. 
The overall process of drug metabolism converts a lipophilic xenobiotic 
which would be stored in the fat depots of the body into a hydrophilic 
conjugate which is readily excreted into the urine via the kidney or 
into the bile. This overall process generally results in detoxication, 
since it converts a hydrophobic compound, the storage of which in the 
body could be associated with toxic effects into a conjugate which,with 
few exceptions, is devoid of physiological effect. 
Phase I of drug metabolism is catalyzed predominantly by the cytochrome 
P-450 enzyme system of the hepatic endoplasmic reticulum (Table 8 ). 
This enzyme system is frequently studied~ vitro using the subcellular 
particles known as hepatic microsomes. Microsomes are vesicles which 
form spontaneously from segments of endoplasmic reticulum following the 
disruption of the endoplasmic reticulum by homogenization of the liver 
tissue. Hepatic microsomes provide an advantageous system for studies 
of drug metabolism since they are easily prepared and collected, and since 
in contrast to the purified reconstituted cytochrome P-450 enzyme system, 
the various components are present in their physiological relationship, 
essentially as found in vivo. Microsomes are thus a useful tool with which 
to study phase I of drug metabolism. 
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4.2 Cytochrome P-450 
4.2.1 Introduction 
Cytochrome P-450 is a group of haem-containing isoenzymes, so named 
because of a striking spectral feature of the CO-ferrocytochrome P-450 
complex, i.e. its absorbance at 450 nm. This group of enzymes is of 
great importance in phase I of drug metabolism, because of its 
extremely broad substrate specificity. For example, substrates for one 
or more forms of cytochrome P-450 include the following: 
aliphatic hydrocarbons, polycyclic hydrocarbons, barbiturates, halogenated 
hydrocarbons, amphetamines, alkanes, fatty acids and polychlorinated 
biphenyls (See Table 9). In addition to the broad substrate speci-
ficity of cytochrome P-450, this group of enzymes also catalyzes a wide 
variety of reactions. Oxidative reactions catalyzed by this cytochrome 
include C-oxidation, N-oxidation, S-oxidation, 0-dealkylation, N-dealky-
lation and deamination. In addition, cytochrome P-450 also catalyzes a 
number of reductive reactions (Tables 9, 10). 
The overall oxidative reaction catalyzed by the microsomal cytochrome 
P-450 enzyme system is accepted to be of the following form, even though 
in many cases, the final stable product may not be hydroxylated. 
+ SH+ NADPH + H + o2 
Cytochrome 
P-450 
SOH + NADPH+ + H20 (Equation l) 
where SH represents the hydrophobic substrate, and SOH its hydroxylated 
product. As shown in Equation l, the rate of metabolism of a compound 
by cytochrome P-450 can be assessed by measuring the rate of oxidation 
of NADPH. According to this equation one mole of NADPH is oxidized per 
mole of substrate hydroxylated. Thus, monitoring the oxidation of NADPH 
as a function of time provides a facile spectral assay for the rate of 
metabolism of diverse substrates by cytochrome P-450. 
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Tab le 9 Metabolism of drugs by cytochrome P-450 in 
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Table 10 






R-CH R-CH -OH 3 2 
N-Dealkylation 
[OH] 




R-S-R I [ R-SOH-R ·] + ---'> R-SO-R I + H+ 
N-Oxidation 
[OH] + 
(CH 3)3N [(CH3)3NOH] + -- (CH3)3NO + H 
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In practice, in experiments conducted with hepatic microsomes, the 
theoretical stoichiometry of 1:1 may not be observed due to oxidation 
of NADPH by side reactions. Following inhibition of cytochrome-mediated 
reactions by CO, corrections for background rates of NADPH oxidation 
in the presence of substrate and C0:02 (80:20) can be made, resulting 
in a closer experimental approximation to the theoretical stoichiometry 
of one mo1 of NAOPH oxidized per mol substrate hydroxylated (see 
Equation 1) (137). 
Cytochrome P-450 haemoproteins are not in themselves capable of 
metabolizing xenobiotics, but require one or more carriers to transfer 
electrons one at a time from the preferred two electron donor NADPH 
to the cytochrome P-450 substrate complex. The overall scheme for 
electron transport for cytochrome mediated reaction is outlined below 
(Fig. 18) (138). Although NADPH is a far more efficient electron donor 
than is NAOH, it has been found that NAOH is an essential electron 
donor for the metabolism of certain compounds by cytochrome P-450. 
For these compounds, cytochrome ~5 is an obligate electron carrier in 
their metabolism by cytochrome P-450. 
Fig. 18 Pathways for electron transfer to cytochrome P-450 (138). 
Straight arrows indicate electron flow, and curved arrows 
indicate reactions occurring. 
NADPH ~- NADPH-cytochrome P-450 reductase _____., cytochrome P-450~2 
~ SH SOH 
NADH NADH-cytochrome ~5 reductase cytochrome ~5 
4.2.l .1. Mechanism for cytochrome P-450 catalyzed oxidative metabolism. 
The accepted mechanism for the metabolism of compounds by cytochrome 








































































































































































































































































































































































a) The substrate binds to active site of cytochrome P-450 resulting 
in the formation of a high spin ferricytochrome P-450 enzyme-
substrate complex. 
b) The ferricytochrome P-450 enzyme-substrate complex is reduced to 
the ferrous form by one electron from NADPH via NADPH-cytochrome 
P-450 reductase. 
c) Molecular oxygen binds to the ferrous ion of the reduced complex. 
d) The ternary complex is further reduced with a second electron 
from NADPH via the appropriate reductase. The superoxide ferrous 
enzyme-substrate intermediate which is formed is in resonance with 
the hydroperoxoferric enzyme-substrate complex. 
e) The 0-0 bond of the hydroperoxoferric enzyme-substrate complex is 
heterolytically cleared to yield water and a ferric enzyme-mono-
oxygen species which is in resonance with the ferryl ion-oxene 
complex. 
f) The hydroxylated product is released,and cytochrome P-450 is 
regenerated in the low spin ferric state. 
Artificial electron donors such as Naro4, NaCl02, H2o2 and organic 
hydroperoxides can support the hydroxylation of a variety of substrates 
by purified cytochrome P-450 in the absence of NADPH, NADPH-cytochrome 
P-450 reductase and molecular oxygen (139, 140). These artificial 
electron donors are thought to function by directly providing cyto-
chrome P-450 with the active oxygen species necessary for hydroxylation 
(Fig. 19). In addition, various model systems have been shown to 
catalyze reactions typical of cytochrome P-450. These systems usually 
comprise haem, a ligand or not, and an electron donor such as thiol or 
NADPH, and have been shown to exhibit aniline hydroxylase and other 
activities typical of cytochrome P-450 (139, 141). 
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4.2.1.2 Cytochrome P-450 catalyzed reductive metabolism 
Cytochrome P-450 has recently been shown to participate in the reductive 
metabolism of xenobiotics such as halocarbons (145-147), polyhalo-
genated compounds (148) and organic nitro and azo compounds (145). 
Such a reductive function of cytochrome P-450 is unexpected 
in view of high affinity of the enzyme for molecular oxygen. However, 
the oxygen concentration in cells is quite low (147) especially in the 
centre of the liver lobules, and this allows reducible lipophilic compounds 
with relatively high oxidation potentials to compete effectively with 
oxygen for electrons at the active site of cytochrome P-450. Under 
these conditions, the reduced form of cytochrome P-450 can transfer one 
or two electrons directly and sequentially to the substrate, resulting 
in substrate reduction and concomitant oxidation of ferrocytochrome 
P-450 to the ferric state (147, 149, 150). Cytochrome P-450 has been 
shown to catalyze the reduction of halothane to a number of products, 
a process which is thought to be associated with the production of 
halothane hepatitis (151). 
4.2.1.3 Binding of compounds to cytochrome P-450 
The first step in the oxidative and reductive metabolism of a compound 
by cytochrome P-450 (see Fig. 20) is the binding of the substrate to 
ferricytochrome P-450. Cytochrome P-450 is perhaps unique in that one 
can easily ascertain whether or not a compound is a substrate simply by 
observing the type of visible spectrum that it produces with the enzyme. 
One can readily obtain spectral binding constants in order to characterize 
substrate binding. This favourable situation occurs because the spin 
state and coordination chemistry of the ferric ion of the haem group of 
cytochrome P-450 are extremely sensitive to ligands and to conformational 
changes in the enzyme caused by binding to the active site or to 
other sites on the enzyme. 
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Fig. 20 Difference spectra with hepatic microsomes. 
460 
Sample cuvette contains hepatic microsomes and compound. Reference cuvette contains 
microsomes alone. Spectral changes represented: type I~~-
type II - - - -; and type IR ........ . 
[Based on Schenkman, 1968 (140), 1970 (157)] 
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Since 1966, it has been appreciated that various substrates and 
inhibitors combine with ferricytochrome P-450 to produce characteristic 
difference spectra with cytochrome P-450 in isolated hepatic micro-
somes (152-155). The changes in the absorbance spectrum caused by 
the binding of compounds to ferricytochrome P-450 are shown in Fig. 20. 
Three binding sites on ferricytochrome P-450 are distinguishable 
spectrally: the type I, IR and II difference spectra. The type I 
difference spectrum is a spectral manifestation of the formation of a 
substrate - ferricytochrome P-450 complex - since compounds which bind 
to the type I binding site of cytochrome P-450 are with few exceptions 
metabolized by cytochrome P-450. The type I difference spectrum has 
been shown to arise from substrate-induced conformational changes in 
the protein which alter the environment and the spin state of the 
haem of ferricytochrome P-450 from a low spin to a high spin state (140). 
The type IR spectrum reflects the conversion of the haem iron atom of 
ferricytochrome P-450 from a high spin to a low spin state (156). 
This change results in a difference spectrum which is the exact reverse 
of the type I difference spectrum (Fig. 20). Compounds displaying 
type IR difference spectra are not bound in the region of the haem 
moiety and consequently are not metabolized by cytochrome P-450 (157). 
The binding of type IR compounds decreases the rate of reduction of 
the cytochrome P-450 complex: the decrease in activity appears to be 
directly related to the magnitude of type IR spectral change (158). 
There are some compounds e.g. hexobarbital, which at low concentrations 
bind to hepatic cytochrome P-450 with the production of a type I 
difference spectrum, but at higher concentrations (5-fold increase) elicit 
a type IR spectrum. 
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In contrast to type I and type IR spectral changes, the type II 
spectral change results from direct liganding of the added xeno-
biotic to the central iron atom of the haem of cytochrome P-450, 
leading to the formation of a low spin ferrihaemochrome. 
(Fig. 20 ). Type II compounds compete with oxygen as a ligand for the 
haem iron ion of ferrocytochrome P-450, and thereby inhibit cyto-
chrome P-450 catalyzed oxidative metabolism (159). Examples of type II 
binding compounds which inhibit cytochrome P-450 dependent metabolism 
are CO and metyrapone (160). 
4.2.l.4 Inhibitors 
SKF-525A (2-diethylaminoethyl-2,2-diphenylvalerate), metyrapone [2-
methyl-1,2-bis (3'-pyridyl)-1-propanone] and CO are considered as examples 
of inhibitors of cytochrome P-450. Fig. 21 (145) shows a hypothetical 
model of the microsomal hydroxylase that results from inhibition 
experiments with SKF 525-A, CO and metyrapone. The substrate and 
oxygen binding sites are also shown therein. 
Fig. 21 A hypothetical model of the microsomal hydroxylase 
(The'mouse trap') [Based on Netter et al 1969 (151 B 
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SKF 525-A exerts a competitive inhibitory effect on the oxidative 
N-demethylation of ethylmorphine. Both SKF 525-A and its metabolite 
are generally considered to be competitive inhibitors of the microsomal 
monooxygenase. As can be seen in Fig. 21, SKF 525-A competes with 
substrates for binding to the type I site. SKF 525-A itself, when 
bound to ferricytochrome P-450, causes a type I spectral change. 
CO and metyrapone bind to the type II binding site, and both interfere 
with the iron-catalyzed activation of oxygen. The curved arrows in Fig. 2i 
serve to symbolize the establishment of actual physical contact between 
the active oxygen and a type I substrate. This concept might also be 
useful in the explanation of competitive inhibition of the oxidation 
of type I substrates (e.g. p-nitroanisole) by metyrapone. Metyrapone 
binds near the haem (site II), but in some instances may partially 
block the type I site. 
4.2.l.5 Induction and multiple forms of cytochrome P-450 
In rat liver endoplasmic reticulum at least ten to fifteen distinct 
forms of cytochrome P-450 have been identified on the basis of electro-
phoretic mobility and immunochemical evidence (see e.g. 161, 162). It 
is expected that ultimately approximately 30 forms will be identified 
(163). The different forms of cytochrome P-450 have distinct amino 
acid compositions, minimum molecular weights, spectral characteristics 
and sensitivities to inhibitors. In addition, the isozymes of cyto-
chrome P-450 differ in their substrate specificities (164-166). 
For example, different forms of cytochrome P-450 may catalyze one type 
of reaction (e.g. biphenyl hydroxylation) at two or more different sites 
on one substrate (167), or they may catalyze different reactions (e.g. 
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N-demethylation and c-hydroxylation) on one substrate. However, there 
are certain activities that are common to several of the multiple forms 
of cytochrome P-450. 
The levels of cytochrome P-450 can be increased~ vivo by a wide variety 
of inducing agents (Table 11) (168-172). The inducing agents often 
selectively increase the levels of one or more forms of cytochrome P-450 
in the mixture of cytochrome P-450 isozymes which is present in the 
liver. The ability of an inducing agent to increase a particular form 
of cytochrome P-450 provides a useful tool for studies of the role of 
distinct isozymes of cytochrome P-450 in the metabolism and toxicity of 
xenobiotics. The nomenclature and properties of some of the inducible 
forms of cytochrome P-450 are summarized in Table 11. 
The most widely used inducing agent for cytochrome P-450 is phenobarbital 
(PB). This agent causes an increase in the isoenzyme termed "the major 
phenobarbital-inducible form of cytochrome P-450" having a molecular 
weight of 51000 daltons (173, 174). This form of cytochrome P-450 
catalyzes the biotransformation of a wide variety of compounds including 
N,N-dimethylaniline, parathion, benzamphetamine and N,N-dimethylphenter-
mine (172, 175). Phenobarbital drastically increases the ability of the 
liver to metabolize certain xenobiotics because it causes proliferation 
of the smooth endoplasmic reticulum in the hepatocyte, increases liver 
weight and elevates the levels of NADPH-cytochrome ~ reductase, cytochrome 
~5• cytochrome P-450, epoxide hydratase and gluc
uronyl transferase per 
mg of microsomal protein (168, 169, 175). 
Pregnenolone-I6a-carbonitrile (PCN) has been demonstrated to act as an enzyme 
inducer for cytochrome P-450 (176). The species of cytochrome P-450 
induced by PCN resembles the phenobarbital type spectrally, but is a 



























































































































































































































































































































































































































































































































































































































































































































































































































































































N-demethylation of benzamphetamine, PCN maximally increases the activity 
for the N-demethylation of ethylmorphine and aminopyrine (172, 177, 178). 
The form of cytochrome P-450 induced by PCN has a molecular weight of 
54000 daltons (173, 174). PCN induction results in an increase in the 
levels of both cytochrome P-450 and NADPH-cytochrome ~ reductase relative 
to the levels of microsomal protein and in the proliferation of the smooth 
surface endoplasmic reticulum in hepatocytes (175). 
The polycyclic hydrocarbons, s-naphthoflavone (BNF) and 3-methylcholan-
threne induce cytochrome P-448 (P1 -450) by a common mechanism (
179). 
Cytochrome P-448 is distinct from the forms of cytochrome P-450 which 
are elevated by pre-treatment of rats with PB or PCN. The molecular weight 
of cytochrome P-448 is 55000 daltons. This form is predominantly 
responsible for the metabolism of polycyclic aromatic hydrocarbons such 
as 3,4-benzpyrene, 7-ethoxycoumarin, 7-ethoxyresofurin, zoxazolamine, 
benzanthracene, naphthalene and phenanthrene and is therefore known as 
aryl hydrocarbon hydroxylase (169). Polycyclic hydrocarbons do not alter 
the levels of the microsomal electron transfer proteins cytochrome ~5 
and NADPH-cytochrome ~ reductase or cause proliferation of the smooth 
surface endoplasmic reticulum, but they do increase the levels of some 
phase II enzymes viz. epoxide hydrase and UDP-glucuronyl transferase. 
The multiple forms of cytochrome P-450 have been named in terms of 
their electrophoretic mobility. For example, rat liver microsomal cyto-
chrome P-448 which is induced by 3-methylcholanthrene is known as LM2. 
However, this system of nomenclature is confusing, since in different 
species LM2 would designate different isozyme
s, e.g. in rabbit, LM2 
would be the major form induced by phenobarbital (172). Therefore, 
in this thesis, the terminology of "phenobarbital inducible form of 




The inducing agents sodium phenobarbital and s-naphthoflavone were 
obtained from Maybaker Ltd., Port Elizabeth, South Africa and 
Aldrich Chemical Company, Milwaukee, Wisconsin, USA, respectively. 
Pregnenolone-16a-carbonitrile was a gift from G.D. Searle and Co., 
Chicago, Illinois, USA. NADPH, and the components of the NADPH-
generating system (NADPH, glucose-6-phosphate and glucose-6-phosphate 
dehydrogenase) were purchased from Miles Laboratories, Cape Town, 
South Africa. Cylinders of pure gases (02 and CO) were obtained from 
Afrox Ltd., Cape Town, South Africa. Metyrapone [2-methyl-1,2-bis 
(3-pyridyl)-1-propane] and SK & F 525-A (s-diethylaminoethyl-2,2-
diphenyl valerate) were gifts from Ciba-Geigy Limited, Basle, 
Switzerland and Smith, Kline and French Ltd., Isando, Transvaal, 
South Africa, respectively. Sodium dithionite was obtained from 
Merck Chemicals, Darmstadt, Germany. All other chemicals were of the 
highest purity commercially available. Water was glass distilled 
and deionized. 
4.2.2.2 Methods 
4.2.2.2.l Experimental animals 
Male Long Evans rats weighing between 190 g and 120 g were used for all 
experiments. The animals were allowed free access to Epol Laboratory 
Chow (protein minimum 20:, fat 2.5~, fibre maximum 6%, calcium 1.4%, 
phosphorus 0.7%) unless otherwise indicated and were allowed free access 
to water at all times. 
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4.2.2.2.2 Treatment of animals 
Different forms of cytochrome P-450 were induced by intraperitoneal 
injection of sodium phenobarbital (80 mg/kg/day in 0.9S saline for 
three consecutive days) or pregnenolone-l6a-carbonitrile (50 mg/kg/day 
in corn oil for three consecutive days), the last injection 16 hrs 
prior to sacrifice, or by one injection of s-naphthoflavone (80 mg/kg/day 
in corn oil 40 hrs prior to sacrifice). All animals were fasted for 
16 hrs prior to sacrifice by cervical fracture. 
4.2.2.2.3 Preparation of hepatic microsomes 
Immediately after the animals were sacrificed, microsomes were prepared 
from fresh rat liver homogenated at 4°c by differential ultracentrifugation 
by a modification of the method of Holtzman and Carr (180). The livers 
from three to eight rats were homogenized in 3 ml of 0.15 M KCl-0.02 M 
Tris-HCl, pH 7.4 per gram wet weight of liver. The cell debris, nuclei 
and mitochondria were removed by centrifugation at 10000 g for 25 min 
in a Beckman J-21B centrifuge. The microsomes were sedimented from the 
supernatant by centrifugation at 105000 g for 55 min in a Beckman model 
L ultracentrifuge. The microsomal pellet was resuspended in 0.15 M 
KCl-0.02 M Tris-HCl and resedimented by centrifugation at 105000 g for 
45 min. The microsomes were finally suspended in 0.02 M Tris-HCl, pH 
7.4 at a concentration of 2 mg microsomal protein/ml and were used within 
5 hours of preparation (181). The protein concentration of the micro-
somal suspension was determined by the method of Lov1ry (182) as modified 
by Chaykin (183) using bovine serum albumin as a standard. 
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4.2.2.2.4 Spectral assays on hepatic microsomes 
4.2.2.2.4.1 Difference spectra 
Two Teflon-stoppered 4 ml cuvettes each containing 2.5 ml of 
microsomal suspension (2 mg protein/ml) were equilibrated to 25°. 
A small volume (5-100 µl) of anaqueous solution of prizidilol was 
added to the sample cuvette below the surface of the microsomal 
suspension using a Hamilton microsyringe. Equal volumes of water 
were added to reference cuvettes. The cuvettes were then stoppered and 
the suspension shaken by hand. The magnitude of the difference spectrum 
was measured as the difference in absorbance between the trough at ca. 
396 nm and the peak at ca. 431 nm at high concentrations of 
prizidilol (24 - 189 µM) or the trough at ca. 416 nm and the peak 
at ca. 380 nm at low concentrations of prizidilol (1 - 23 µM). 
Correction was made for the intrinsic differences in absorbance at these 
wavelengths for cuvettes containing microsomal suspension only. 
4.2.2.2.4.2 Cytochrome P-450 assay 
The concentration of cytochrome P-450 in hepatic microsomes was 
determined from measurement of the difference spectrum of CO-ferro-
cytochrome P-450 versus ferrocytochrome P-450, as described by Omura 
and Sato (184). Two Teflon-stoppered 4 ml cuvettes each containing 
2.5 ml of microsomal suspension (2 mg protein/ ml) were equilibrated 
0 to 25 . The sample cuvette was bubbled with CO (30 ml/min) for 30 sec. 
A few grains of sodium dithionite were added to each cuvette, and the 
absorbance difference spectrum was measured from 500 nm to 410 nm. 
The extinction coefficient used for the difference between the absorbance 
at 450 nm and 490 nm was 91 mM-l cm- 1. 
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4.2.2.2.5 Spectrophotometry 
All spectral measurements were performed using a Beckman 5230 
recording spectrophotometer. In all cases,cuvettes with a pathlength 
of 1 cm were used in the compartment adjacent to the photomultiplier. 
4.2.2.2.6 Metabolism of prizidilol 
4.2.2.2.6. 1 NADPH oxidation 
The metabolism of prizidilol was measured by monitoring the rate 
of hepatic microsomal NADPH consumption in the presence of prizidilol 
in the presence and absence of C0:02 (80:20; v/v). T'.'10 Teflon-stopper
ed 
4 ml cuvettes each containing 2.5 ml of microsomal suspension (2 mg 
protein/ml) were equilibrated to 25°. Varying amounts of a solution 
of prizidilol (14.2 µMor 142 µM) were added to the sample cuvette. 
The reaction was initiated with the addition of 50 µl of NADPH 
(0.12 mM final concentration) to the sample cuvette. Background 
rates were measured with the presence of prizidilol and C0:02 (80:20). 
The decrease in absorbance at 340 nm was recorded. The 
reported rates for the oxidation of NADPH were calculated 
. -1 -1 
using E340 nm of 6.2 mM cm 
(185). 
4.2.2.2.6.2 Incubation mixtures 
Prizidilol disappearance was assayed in incubation mixtures containing 
prizidilol (varying concentrations), NADPH generating system 
[NADPH (0.4 mM), glucose-6-phosphate (7.5 mr·1), glucose-6-phosphate 
dehydrogenase (0.5 units per ml), MgC1 2 (5 mM), EDTA (0.2 mM), 
nicotinamide (1 mM)] and hepatic microsomes (2 mg protein/ml) in 0.02 M 
Tris-HCl, pH 7.4. Where inhibitors of cytochrome P-450 were present, 
they were added to the microsomal suspension prior to the introduction 
of the prizidilol. 
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Incubations were carried out at 37° in a B & T Laboratory Thermal 
Equipment shaking water bath with shaking at 60 oscillations per min. 
The reaction was stopped by the addition of 100 µl of orthophosphoric 
acid solution (see 2.2.2.1.1.) and 100 µl pepsin solution. Then 
100 µl of internal standard (2 µg/100 µl in water) and 50 µl of 
quinolin-3-al were added. The above samples were mixed vigorously 
with a vortexing mixer. Prizidilol was extracted and assayed as 
described in sections 2.2.3.2.l and 2.2.3.2.3 respectively. 
4.2.2.3 Statistical analyses 
Student's t test for unpaired data (SD based on n-1) 
was utilized to calculate significant differences between means. 
P < 0.01, being significant, p < 0.05 being probably significant. 
Each piece of data represents the results of a single incubation 
mixture, not one of several determinations on a single incubation. 
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4.2.3 RESULTS 
4.2.3.l The binding of prizidilol to hepatic microsomal cytochrome P-450 
Prizidilol exhibited two distinct types of difference spectra with 
hepatic microsomal cytochrome P-450. With low concentrations 
(1 - 23 µM) of prizidilol, a type I difference spectrum 
()._ . = 416 nm: ::>\ = 380 nm) was obtained. In contrast, high min max 
concentrations (24 - 189 µM) of prizidilol resulted in the production 
of a type II difference spectrum (~in= 396 nm; :>-..max= 431 nm). 
(See Fig. 22). The effects of induction of different forms of 
cytochrome P-450 on the binding of prizidi1ol to hepatic cytochrome 
P-450 was assessed: 
Hanes plots for the binding of prizidi1ol to cytochrome P-450 in 
hepatic microsomes from uninduced, phenobarbital, pregneno1one-I6a-
carbonitri1e and s-naphthoflavone induced rats were biphasic, with Ks 
values for low concentrations (1 - 23 µM) (type I binding) and 
high concentrations (24 - 189 µM) (type II binding) of prizidilol 
being calculable (Figs. 23-26). 
The effect of induction of different forms of cytochrome P-450 on the 
binding constant (Ks) and the maximum extent of binding (6Amax) for 
the binding of prizidilol to hepatic microsomal cytochro~e P-450 in 
the type I and type II manner is presented in Tables 12 and 13 
respectively. Pretreatment of rats with s-naphthoflavone, pregnenolone-
16a-carbonitrile or phenobarbital did not result in significant 
alterations in the values of K, 6A or 6Amax/nmol microsomal cyto-s max 
chrome P-450 for the binding of prizidilol (low concentrations) to 
the type I site (Table 12). For the binding of the high concentration 
of prizidilol to the type II site, the value of Ks was significantly 












Difference spectra of hepatic microsomes (2 mg protein/ml) 
from phenobarbital treated rats at 300 (-----) no addition; (~-) 
190 µM prizidilol added to sample cuvette (~·~); 23 µM 
prizidilol added to sample cuvette. 
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5 25 50 100 150 200 
PRIZIDIIDL ( µ M) 
Fig. 23 Hanes plot for the binding of prizidilol to cytochrome P-450 in 
hepatic microsomes from untreated rats. 
6A = A4 31 nm - A396 nm for high concentrations o
f prizidilol (>24 i.J1)(0) 
Ks= 327 µM t:,A = 0.54 
t:,A = A 380 nm A416 nm for lov1 concentration of prizidilol (
1-23 wM) (a) 
















5 25 50 100 150 200 
PRIZIDHDL ( µ M) 
Fig. 24 Hanes plot for the binding of prizidilol to cytochrome P-450 in 
hepatic microsomes from phenobarbital pretreated rats. 
tA = A431 nm - A395 nm for high concentration of prizidilol (>24 wM) (e) 
Ks= 78.7 µM tA = 0.92 
t-..A = A330 nm - A416 nm for low concentration of prizidilol (1-23 µM) (•) 
















5 25 50 
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100 
PRIZIDIWL ( µ ~-1) 
150 200 
Hanes plot for the binding of prizidilol to cytochrome P-450 in 
hepatic microsomes from pregnenolone-16 a -carbonitrile pretreated 
rats. 
LA= A431 nm - A395 nm for high concentration of pr
izidilol (>24 uM) (•) 
Ks= 232 µM LA= 0.78 
LA= A38Q nm - A4 15 nm for low concentration of prizidilol (1-23 µM) (•) 
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100 
PRIZIDILOL ( µ M) 
150 200 
Fig. 26 Hanes plot for the binding of prizidilol to cytochrome P-450 in 
hepatic microsomes from B-naphthoflavone pretreated rats 
6A = A431 nm - A396 nm for high concentrations of prizidilol (>24 µM) (G) 
Ks = 120 µM 6A = 0.38 
6A = A3go nm - A416 nm for low concentrations of prizidilol 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































but not pregnenolone-16a-carbonitrile treatment. The value of 6A max 
was significantly increased following pregnenolone-16a-carbonitrile 
or phenobarbital treatment but not s-naphthoflavone treatment (Table 13). 
For the binding of prizidilol to the type II site, there were no signi-
ficant changes in 6A /nmol cytochrome P-450, following any type of max 
pretreatment. 
4.2.3.2 Prizidilol stimulation of hepatic microsomal CO-inhibitable NADPH oxidation 
The rate of NADPH oxidation in the presence of a xenobiotic is in 
theory a valid method for measuring the metabolism of that compound by 
hepatic microsomal cytochrome P-450. In practice, it is found that 
significant background rates of NADPH oxidation occur. Therefore, 
the observed rates of NADPH oxidation are corrected for the rate in 
the presence of the drug and C0:02 (80:20). In the latter situation, 
the CO will inhibit all cytochrome P-450 dependent metabolism and allow 
measurement of a background rate which can be subtracted for the 
observed rate in the presence of drug and absence of CO. Thus the rate 
of prizidilol stimulated CO-inhibitable NADPH oxidation should provide an 
accurate reflection of the metabolism of prizidilol by hepatic 
microsomal cytochrome P-450. 
Prizidilol stimulated CO-inhibitable NADPH oxidation in hepatic 
microsomes from uninduced and pretreated rats (Fig. 27) (Tables 14 and 
15). The effect of pretreatment of rats with inducing agents for 
cytochrome P-450 on the initial rates of hepatic microsomal oxidation 
of NADPH in the presence of prizidilol, ~lith and without C0:02 (80:20), 
is shown in Tables 14 and 15. With a low concentration of prizidilol 
(14.2 µM), pretreatment of rats with s-naphthoflavone or pregnenolone-
16a-carbonitrile did not significantly alter the rate of CO-inhibitable 
NADPH oxidation per mg microsomal protein. But microsomes from rats 
pretreated with phenobarbital exhibited significantly increased 
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142 µM prizidilol + C0:02 
14 µM prizidilol + C0:02 
142 µM prizidilol - C0:02 
14 µM prizidilol - C0:02 
0 0,5 1,0 1,5 2,0 
Time (min) 
Fig. 27 Prizidilol stimulated NAOPH oxidation with hepatic 
microsomes from pretreatment of rat with phenobarbital 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































rates of NADPH oxidation per mg microsomal protein. No type of 
pretreatment altered the rates of CO-inhibitable NADPH oxidation per 
nmol cytochrome P-450 (Table 14). 
With a high concentration of prizidilol (142 µM), the rate of prizidilol 
stimulated CO-inhibitable NADPH oxidation per mg protein was not 
affected by pretreatment of the rats with phenobarbital, but was signifi-
cantly diminished following pre-treatment with pregnenolone-16a-carbo-
nitrile or s-naphthoflavone. CO-inhibitable NADPH oxidation per 
nmol cytochrome P-450 was significantly diminished by all pretreatments 
(Table 15). For microsomes from untreated rats the rates of CO-
inhibitable NADPH oxidation were identical for the low and high 
concentrations of drug. However, CO-inhibitable NADPH oxidation per 
mg protein and per nmol cytochrome P-450 was significantly lower with 
142 µM prizidilol versus 14 µM prizidilol for all types of pretreatment 
(Tables 14 and 15). 
4.2.3.3 Hepatic microsomal metabolism of prizidilol 
The disappearance of prizidilol in incubations containing NADPH-genera-
ting system and hepatic microsomes from uninduced or pretreated rats 
is shown in Fig. 28. The disappearance of prizidilol with microsomes 
from phenobarbital-pretreated rat was linear for 10 minutes. With 
microsomes from pregnenolone-16a-carbonitrile or s-naphthoflavone 
treated and control rats, prizidilol was lost rapidly for a short period 
(up to 3 min) and subsequently (between 3 and 20 min), the loss of 
prizidilol was linear. The time periods used for incubations to 
determine K and V values were 10 min for microsomes from phenobarbital m max 
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Effect of incubation with NADPH-generating system plus hepatic microsomes 
(2 mg protein/ml) from untreated or pretreated rats on prizidilol concentration 
as a function of time. Abbreviations used are sNF, s-naphthoflavone; 
PCN, pregnenolone-l6a-carbonitrile; PB, phenobarbital. 
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4.2.3.3.l Inhibition of the metabolism of prizidilol in 
hepatic microsomal cytochrome P-450. 
The effect of inhibitors of cytochrome P-450 on the disappearance of 
prizidilol in incubation mixtures containing NADPH-generating system 
and hepatic microsomes from rats pretreated with phenobarbita1 
is given in Table 16. Metyrapone (1 mM), SKF 525-A (200 mM) and 
C0:02 (80:20 v/v) a11 effectively inhibited the metabolism
 
of prizidilol by hepatic microsomes. As inhibitors of prizidilol 
disappearance, metyrapone and SKF 525-A were equivalent while CO 
was slightly less effective. 
4.2.3.3.2 Prizidilol disappearance 
Hanes plots for the disappearance of prizidilol from incubations of 
NADPH-generating system plus microsomes from rats pretreated with 
phenobarbital, pregnenolone-16a-carbonitri1e, s-naphthoflavone and 
uninduced rat are shown in Figs. 29-32. Pretreatment of rats with 
phenobarbital increased the values of Km and Vmax (nmol/min/mg 
microsomal protein) relative to microsomes from untreated rats 
(Table 17). Pretreatment of rats with s-naphthof1avone or pregnenolone-
16a-carbonitri1e did not significantly alter the values of K or V m max 
(nmol/mg microsomal protein/min) (Table 17 ). The values of V / max 
cytochrome P-450/min were not affected by the pretreatment of rats with 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.3 GSH S-Transferases 
4.3.1 Introduction 
Glutathione (GSH) S-transferase B, the major GSH S-transferase of 
rat 1iver, was first described in 1959 (186). The GSH S-transferases 
catalyze the conjugation of GSH with a large number of compounds 
bearing an e1ectrophi1ic carbon to form a corresponding thioether. 
A number of substrates for the GSH S-transferases are shown in Fig. 33. 
The thioether adducts are subsequently acted upon by other enzymes 
which remove glutamate and glycine and which acetylate the amino group 
of the resultant thioether of cysteine. The N-acetyl cysteine thioether 
derivative is known as the mercapturic acid derivative of the substrate 
and is usually a non-toxic, water soluble product which is readily 
excreted. This pathway is shown in Fig. 34. Mercapturic acids are 
generally the major products of drugs primarily metabolised by GSH 
conjugation. 
In the early nineteen sixties, the GSH S-transferases were implicated 
in the metabolism of insecticides (187 ). The GSH S-transferases 
catalyse two main types of reaction with these insecticides which include 
organophosphorus triesters, organothiocyanates and chlorinated hydro-
carbons, i.e. the formation of S-alkyl or S-aryl conjugates, both 
of which result in detoxication, the former appearing to be the major 
metabolic pathway~ vivo (188). The insect GSH S-transferases exhibit 
multiplicity with insecticides as substrates (189), i.e. several enzymes 
may be active with a specific compound. Each enzyme may also display 




















CH2tHC CH3 6! 
CH2SG 
OO+H2S04 
Fig. 33 Substrates for the GSH S-transferases. 
The reactions shown are between GSH and (1) 1.2-dichloro-4-nitrobenzene 
(186); (2) 1-chloro-2,4-dinitrobenzene (both are aryl substrates) (190); 
(3) trans-4-phenyl-3-butan-2-one (an alpha, beta-unsaturated ketone) (191); 
(4) l,2-epoxy-3-(p-nitrophenoxy) propane (an epoxide) (192); 
(5) menapthyl sulphate (a sulphate ester) (193) and (6) iodomethane 














R SCH2CH I + Glutamate 
NH 2 l Cysteinylglycinase 
COOH 
I 
R SCHz,H + Glycine 
NH 2 
Acetyl-CoA ~ Acetyltransferase 
COOH 
I 
R SCH2CH I 
NHCOCH3 
Fig. 34 Metabolic pathway for the biosynthesis of the 
mercapturic acid. RX represents an electrophilic compound. 
[Based on Boyland and Chasseaud 1969 (186D 
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enzymes of rat liver (184). Multiple forms of GSH S-transferase 
exist in all species studied. For example, rat liver has seven 
isoenzymes, which vary in amino acid composition and isoelectric point 
but are similar in size and overlap in substrate specificity. They are 
thought to be the product of at least 6 genes. 
4.3.l.l Rat liver cytosol GSH S-transferases 
Generally, hepatic tissue has greater GSH S-transferase activity than 
extrahepatic tissue. However, GSH S-transferase activity was also 
detected in kidney, small intestine mucosa, testis, ovary and adrenal 
gland. Lesser quantities were present in salivary gland, gastric mucosa 
of colon, pancreas, pituitary, lung, thyroid, bladder, heart and seminal 
vesicles (195). 
The GSH S-transferases represent approximately 10~ of soluble rat liver 
protein. The major transferase of rat liver is GSH S-transferase B 
which accounts for 5% of the total cytosolic protein (196). 
The properties of seven rat cytosol GSH S-transferases are listed 
in Table 18. In one form of nomenclature, the isozymes are designated 
as E,D,C,B,A and AA, in order of their elution from carboxymethyl-
cellulose cation exchange columns (197, 198). The separation depends 
on the observation that each GSH S-transferase has a distinct 
isoelectric point within the range pH 7 to 10. An additional 
transferase, GSH S-transferase M, which binds to diethylaminoethyl-
cellulose (DEAE-cellulose) at pH 8.0 and catalyzes the reaction of 
GSH to 1-menapthyl sulfate,has been purified to homogeneity (199). 
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Table 18 Multiple forms of the rat liver GSH 
ana su6strate soec1r1c1t1es. 
PROPERTY AA A B 
M Weights 45000 46000 47000 
s/u 25000 23000 22 + 
YcYc YbYb YaYc 
Reaction with none A, C B 
antibody 
Isoelectric 10 8.9 9.8 
point 
Relative concen-
tration 0.14 0.22 1.0 
Substrate specific activities (µmol/min/mg) 
CDNB 14 62 11 
DCNB 0.008 4.3 0.003 
IM 1.4 0 0.59 
EA 0.3 0 0.26 
pNBC 0.09 11. 4 0.1 
tPBO 0 0.02 0.001 
so 
MS 0 0.004 
BSP 0.53 0.006 
Prostaglandin A1 0.013 0.005 
t::,.5-Androstene-3, .001 0.01 1. 87 
17, dione 
Abbreviations used are: 
- reduced glutathione 
- l-chloro-2.4-dinitrobenzene 
- 2.4-dichloronitrobenzene 
- p-nitrobenzyl chloride 
- styrene oxide 



























tPBO - trans-4-phenylbut-3-en-2-one 














[Based on Jakoby et al 1976 (213) Jakoby and Habig 1980 (21+) and Habig and 







Rat GSH S-transferases A and Care structurally and immunologically 
similar, and they differ only in isoelectric point. None of the other 
rat liver GSH S-transferases appear to share immunological identity. 
The specific activity of GSH S-transferases Band AA with the substrate 
CDNB (l-chloro-2.4-dinitrobenzene) is several times greater than that 
with DCNB (2,4 dichloronitrobenzene) while GSH S-transferases A and C 
both have considerable activity with DCNB. GSH S-transferases A and C 
differ in their ability to catalyze the reaction of GSH with the sub-
strate trans-4-phenyl-3-bute-2-one, the specific activity of GSH S-
transferase C being 20-fold higher than A (200). The amino acid 
composition of rat GSH S-transferases A and Care similar (201), while 
the other transferases showed much less similarity (202). 
4.3.l.2 Human GSH S-transferases 
Five basic GSH S-transferases have been isolated from human liver. 
These are designated alpha, beta, gamma, delta and epsilon in order of 
increasing isoelectric point (pl 7.8 - 8.8) (203). These proteins 
have similar amino acid compositions and molecular weights (48000 
daltons), and each is a homodimer of two identical subunits. The 
delta protein accounts for the major portion of the hepatic transferases. 
All five basic human transferases react similarly with monospecific 
antibody prepared against each of the other four proteins (204). 
In addition to the basic transferases, acidic transferases have been 
demonstrated in human liver (205, 206). Significant differences 
in catalytic properties of cationic, anionic and neutral forms have 
been noted (207, 208). GSH S-transferase activity has also been 
documented in human erythrocytes (209), lymphocytes, peripheral leuco-
cytes (210) and placenta (211, 212). 
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4.3.2 Experimental 
4.3.2. 1 Materials 
All reagents used were of analytical grade and were purchased as 
detailed below: Human serum albumin (crystalline) from Miles 
Laboratories (Pty), Ltd., Goodwood, South Africa. Glutathione (Type IV) 
was obtained from Sigma Chemical Co., St. Louis, Missouri, USA. 
4.3.2.2 Methods 
4.3.2.2.l Preparation of cytosol 
Male Sprague-Dawleys rats (190-210 grams) were sacrificed by cervical 
fracture. The liver was rapidly removed and following initial frag-
mentation with scissors, homogenization was carried out in 0.01 M 
sodium phosphate buffer pH 7.4/0.25 M sucrose; sufficient buffer was added 
to yield a 25% (w/v) homogenate. The initial centrifugation was at 
27000 g for 30 minutes in a Sorvall RC-5 super speed centrifuge. 
The supernatant fraction was carefully removed without disturbing 
the floating lipid layer and centrifuged at 100000 g for 120 minutes 
in a Beckman model L5.35 ultracentrifuge. The supernatant was removed 
as before and stored on ice. The cytosol (post-microsomal superna-
tant) was finally added to the test tube at a concentration of 3.5 mg 
protein per ml. 
4.3.2.2.2 Prizidilol disappearance in rat liver cytosol 
Prizidilol (1.7 µM) was added to cytosol (3.5 mg/ml protein) and 
mixed vigorously with a vortexing stirrer. The reaction was initiated 
with GSH (10 mM) then allowed to proceed at 37°C for 15 or 30 minutes 
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with shaking at 60 oscillations per minute. The estimation of 
prizidilol was described in sections 2.2.3.2.l and 2.2.3.2.3. 
4.3.3 Results 
The effect of incubation of prizidilol with rat liver cytosol and 
GSH is reported in Table 19. There is not a statistically 
significant decrease in the concentration of prizidilol after incu-
bation of prizidilol with cytosol for 15 or 30 minutes. These 
results indicate that rat liver cytosol GSH S-transferases do not 
effectively catalyze the metabolism of prizidilol, and that prizi-












































































































































































































































































































































































4. 4. 1 Introduction 
Acetylation is a major route for the metabolism of aromatic amines in 
many different species (216). The liver cytosolic N-acetyltransferases 
catalyze the acetylation of a number of commonly used drugs and 
foreign compounds such as isoniazid, sulfamethazine, p-aminobenzoic acid, 
hydralazine and diaminodiphenylsulphone, in man and certain other 
mammalian species (217). Selected substrates for the acetyl trans-
ferases are shown in Table 20. 
The activity of the acetyltransferases varies widely between species. 
For example, the rabbit has a relatively high capacity to acetylate 
sulfanilamide on the N4-position. The human has a moderate capacity 
for this process, while other species, including the dog and fox,are 
unable to acetylate sulfanilamide in that position but can acetylate 
the sulfonamido group and excrete N-acetylsulfonamide. These results 
indicate the existence of more than one form of the N-acetyltransferases 
(218). 
The N-acetylation of xenobiotics in man exhibits a hereditary poly-
morphism, which is readily observable in the rate of drug acetylation 
(219). For this reason, people can be classified as either rapid or 
slow acetylators of isoniazid and certain other arylamine and hydrala-
zine drugs. No biochemical basis for the acetylation polymorphism has 
as yet been found, viz. the characteristics of N-acetyltransferase 
prepared from rapid and slow acetylator livers appear to be identical 
(220, 221 ) . 
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[Based on Hearse DJ and Weber WW 1973 (217)] 
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The N-acetyltransferases are cytosolic enzymes which are found in 
many tissues of a number of species (222, 223). The cellular 
distribution differs from species to species. For example, in rabbit 
the enzyme appears in the reticuloendothelial cells and not in hepatic 
cells (224), \vhile in rat liver,activity is found both in the 
reticuloendothelial (225) and hepatic cells (226). In the gastro-
intestinal tract, enzyme activity occurs in mucosal elements but not 
in connective or muscle tissue. Activity is also present in cells of 
peripheral blood, but not in plasma, fat or skeletal muscle (227). 
N-acetyltransferase activity exhibits a broad temperature optimum; 
the temperature optimum for the purified enzyme from slow and fast 
acetylators being from 25° to 45° C, \vith a peak at 37°c. The pH 
profile of the activity of human liver N-acetyltransferases purified 
from both slow and fast acetylators was biphasic with peaks at pH 
6.6 and pH 7.2. In both cases, the specific activity was relatively 
greater at the lower pH (228). N-acetyltransferase activity is 
. . . ++ ++ ++ ++ ++ ++ ++ 2 1nh1b1ted by Cu , Hg , Zn , Cd , Ca , Mn and Fe ( 28). 
4.4.2 Experimental 
4.4.2.1 Materials 
Acetyl Coenzyme A was obtained from Sigma Chemical Co., St. Louis, 
Missouri, USA. Cuprous chloride was purchased from May and Baker 
Ltd., Poole, England. Manganese sulfate and ammonium sulfate were 
obtained from BDH Ltd., London. N-acetyltransferase was purified from 
rat liver cytosol (100000 g supernatant) by differential precipitation 
with ammonium sulfate and chromatography as described in section 4.4.2.2.2. 
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4.4.2.2 Methods 
4.4.2.2.l Determination of activity of N-acetyltransferases of cytosol 
Rat liver cytosol (post-microsomal supernatant) was prepared according 
to section 4.3.2.2.1. The protein concentration of the cytosol was 
measured by the method of Lowry et al (182). The N-acetyltransferase 
activity of cytosol was measured by the rate of disappearance of 
prizidilol from incubation mixtures containing prizidilol (3.7 µM), 
acetyl CoA (l mM) and cytosol (0.8 mg protein/ml). Incubations were 
carried out at 37°c in a B & T Laboratory Thermal Equipment shaking 
water bath, with shaking at 60 cycles per minute. 
4.4.2.2.2 Purification of rat liver N-acetyltransferases 
100 ml of rat liver cytosol was made to 50~ saturation with respect 
to ammonium sulfate by the addition of a saturated solution of this 
salt. After 10 min, the precipitate was removed by centrifugation 
and the supernatant fraction was adjusted to 70~ saturation with 
respect to ammonium sulfate. The precipitate obtained was dissolved 
in 30 ml of 0.01 M phosphate buffer (pH 7.0). This solution was further 
fractioned by gel filtration on a Sephadex G-100 column (2.5 cm x 50 cm) 
using 0.005 M phosphate buffer, pH 7.2. The protein concentration of 
this preparation was measured by the method of Lowry et al (182). 
The fractions from this column with activity for the acetylation of 
prizidilol were combined. Figure 35 shows protein concentration and 
the activity of N-acetyltransferase in each fraction. 
4.4.2.2.3 Determination of activity of the purified N-acetyltransferases 
Purified N-acetyltransferases were assayed for prizidilol acetylating 
activity by measuring the rate of disappearance of prizidilol from 























The protein concentration (Absorbance 280 nm) and 
N-acetyltransferase activity of fractions from the 























I ' ~~ 
I \ • •. 
I ' • • 
I ', : : 
I ' • : '-', . 
I : ' 
I ', • 
I • .,, • 
I '~ 
I ~ 
I • ' 
I • : ', 
/ : ',, 
I ,, 
I • • ', 
/ . ' 
I ' I ',, 
I ,, , ~ 
/ .. .... ......... 
,,• 
10 20 30 40 
Fraction Number 
The protein concentrations were measured at Absorbance 280 nm. N-acetyltransferase activity were measured by the loss 













































constructed, and enzyme activity was determined from the linear 
portion of the curve (see e.g. Fig. 36). All incubations were 
carried out at 37° in 3 ml stoppered vials with shaking at 60 
cycles per minute. The reaction mixture consisted of enzyme solution 
(2 mg protein concentration/2.5 ml) acetyl CoA (1 mM) and prizidilol 
(3.7 µM). Control vials contained no acetyl CoA. The reaction was 
initiated by the addition of the enzyme preparation and the vials 
(two for each time point) were capped and incubated for 30 min. 
The reaction was terminated by the addition of 100 µl of orthophosphoric 
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4.4.3.l The enzymatic acetylation of prizidilol by rat liver cytosol 
The biotransformation of prizidilol by the rat cytosolic acetyltrans-
ferases was assayed by the disappearance of prizidilol from reaction 
mixtures after incubation in the presence of acetyl CoA (1 mM), 
post mitochondrial supernatant or partially purified enzyme and 
prizidilol (0-4 µM) in 0.01 M phosphate buffer, pH 7.0. The effect 
of time on the loss of prizidilol is shovm in Fig. 36 and summarized 
in Table 21. 
There was no significant loss of prizidilol when acetyl CoA (Table 21) 
(Fig. 36) or cytosol (data not shown) was omitted from incubation 
mixtures. These results suggest that the disappearance of prizidilol 
reflects its acetylation and that a non-enzymatic acetylation was not 
occurring. The disappearance of prizidilol with cytosol was linear for 
30 minutes (Fig. 36), and this time period was used for further 
incubations to study the acetylation of prizidilol with hepatic cytosol 
acetyltransferases. 
The loss of prizidilol per 30 min was shown to increase linearly with 
respect to the concentration of cytosol added, up to 5 mg protein/2.5 ml 
incubation mixture (Fig. 37). 
4.4.3.2 The acetylation of prizidilol by the purified rat liver N-acetyl-
transferase 
The loss of prizidilol as a function of time, at various concentrations 
of partially purified acetyltransferase is shown in Fig. 38. The 



































































































































































































































































































































































































































































































































































































































































































































































































of enzyme studied. This time period was used in all further 
incubations, e.g. to determine Michaelis constant (K) and maximal m 
velocity (V ) for the metabolism of prizidilol by the acetyltrans-max 
ferases. 
There was no loss of prizidilol from reaction mixtures which contained 
the enzyme but not acetyl CoA (Fig. 39, Table 22). There was no loss 
of prizidilol when acetyl CoA and prizidilol were incubated together 
in the absence of purified N-acetyltransferase, suggesting that a 
non-enzymic acetylation was not occurring (Fig. 40, Table 23). There 
was also no disappearance of substrate in reaction mixtures containing 
prizidilol and a preparation of acetyltransferase that had been heated 
for 10 min at 90° before incubation (Fig. 40, Table 23). The effect 
of enzyme concentration on the loss of prizidilol is shovm in Figs. 38, 41. 
The plot approximated linearly for up to 200 µl of enzyme solution. 
The effects of inhibitors of N-acetyltransferase on prizidilol disappearance 
are given in Fig. 40 and Table 23. Cuprous chloride (0.14 mM) and 
Manganese sulfate (0.14 mM) were all effective inhibitors of the 
metabolism of prizidilol by N-acetyltransferases. Table 23 shows that 
cuprous ion inhibited N-acetyltransferase activity towards prizidilol 
by 69~, whereas manganese ion inhibited this process by 51%. 
The effect of acetyl CoA concentration and prizidilol concentration on 
the acetylation of prizidilol by purified rat liver cytosol acetyl-
transferase is shown in Fig. 39 and Table 22. K and V values m max 
were calculated from Hanes plots of these data (Figs. 42 and 43). 
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15 µM acetyl CoA 
CoA 
50 µM acetyl CoA 
100 µM acetyl CoA 
I 
· 150 µM acetyl CoA 
l 
30 
Effects of various concentrations of acetyl CoA on the 
disappearance of prizidilol. The volume of purified 
N-acetyltransferase (7.7 mg protein/ml) was 300 µl. 
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Fig. 40 Effect of inhibitors of N-acetyltransferase on the disappearance 
of prizidilol. The volume of purified N-acetyltransferase 
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Effects of various concentrations of purified N-acetyl-
transferases (12 mg protein/ml) on the disappearance 
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The value of the K for prizidilol was 0.78 µM; the maximum velocity m 
of the reaction V was 0.98 µmol/min; and the K for acetyl CoA was max ~ 
22 ± 0. 17 µM. 
4.4.3.3 Metabolite identification 
The levels of prizidilol were decreased following the incubation 
of prizidilol with reaction mixtures containing liver cytosol or par-
tially purified N-acetyltransferase and acetyl CoA. An increase in 
the production of cyclised acetylated prizidilol was found in the 
TLC method for the determination of quinolin-3-al derivatived 
prizidilol, SKF 93238 and cyclised acetylated prizidilol. Unfortunately, 
the yield of cyclised acetylated prizidilol vJas very low and v1as even 
affected by the background, so using isotopically labelled acetyl CoA 
will be recommended to confirm the metabolite identification. 
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5. DISCUSSION 
The results presented herein demonstrate that hepatic cytochrome P-450 
and cytosolic N-acetyltransferases but notGSH S-transferases are 
involved in the metabolism of prizidilol. 
That cytochrome P-450 catalyzes the metabolism of prizidilol is 
supported by the following evidence: 
1. Prizidilol bound to the active site of the enzyme as evidenced by 
the production of a type I difference spectrum with a low 
concentration (<23.7 µM) of prizidilol and displayed a type II 
difference spectrum with a high concentration (24 - 190 µM) of 
prizidilol. 
2. Prizidilol stimulated CO-inhibitable NADPH oxidation with hepatic 
microsomes, which is a measure of cytochrome P-450 dependence 
metabolism. 
3. The inhibitors of cytochrome P-450 - CO, metyrapone and SKF 525-A 
inhibited the disappearance of prizidilol in the presence of 
hepatic microsomes and NADPH-generating system. 
With the aid of inducing agents such as phenobarbital, s-naphthoflavone, 
and phenobarbital which elevate the levels of specific forms of hepatic 
cytochrome P-450, the role of different forms of the enzyme in the 
binding and metabolism of prizidilol in hepatic microsomes was 
investigated. With a low concentration of prizidilol, multiple forms of 
cytochrome P-450 appear to bind and metabolize prizidilol. The form 
of cytochrome P-450 elevated by s-naphthoflavone or pregnenolone-16a-
carbonitrile did not appear to bind or metabolize prizidilol extensively; 
while the phenobarbital inducible form did. s-Naphthoflavone and 
pregnenolone-16a-carbonitrile did not affect the values of K and did 
s 
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not alter or decrease 6A and 6A per nmol cytochrome P-450 max max 
for the binding of prizidilol. 
Pretreatment of rats with s-naphthoflavone or pregnenolone-16a-
carbonitrile did not result in significant alterations in the values 
of K, 6A or 6A /nmol microsomal cytochrome P-450 for the binding of s max max 
prizidilol (1 - 23 µM) to the type I site (Table 12). 
In addition the rates of the disappearance of prizidilol per 2 mg 
microsomal protein and per nmol cytochrome P-450 were not affected 
following s-naphthoflavone or pregnenolone-16a-carbonitrile induction. 
The phenobarbital inducible form of cytochrome P-450 appears to play 
a minor role in the metabolism of prizidilol. Phenobarbital did not 
affect K, 6A or 6A per nmol cytochrome P-450 for the binding s max max 
of prizidilol to the active site (Table 14). Phenobarbital 
significantly increased prizidilol (14 µM), stimulated hepatic 
microsomal NADPH oxidation and V for prizidilol metabolism per max 
mg protein, but did not affect either parameter per nmol cytochrome 
P-450 (Tables 14 and 17). 
It is proposed that one or more of the forms of cytochrome P-450 present 
in microsomes from untreated and phenobarbital treated rats, function 
efficiently in the metabolism of prizidilol. 
Prizidilol appears to inhibit its own metabolism by hepatic microsomal 
cytochrome P-450; prizidilol bound to the type II site of the enzyme 
(Table 13, Fig. 22). The binding of prizidilol to this site competes 
directly with the binding of the required co-factor oxygen; the binding 
constant for this interaction ranges from 70 to 300 µM. Concentrations 
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of prizidilol in this range significantly inhibited the ability 
of prizidilol to stimulate hepatic microsomal NADPH oxidation 
(Table 14 and 15). 
The effect of inducing agents on the binding of prizidilol to the 
type II site are as follows: s-naphthoflavone and phenobarbital 
significantly decreased the value of K and pregnenolone-16a-s 
carbonitrile and phenobarbital significantly increased the values of 
tAmax· No type of pretreatment affected tAmax/nmol cytochrome P-450 
(Table 13). For all types of pretreatment high concentration of 
prizidilol _diminished CO-inhibitable NADPH oxidation. 
The GSH S-transferases in rat liver cytosol did not decrease the 
levels of prizidilol after 30 minutes on the incubation of prizidilol 
with cytosol, indicating that liver cytosolic GSH S-transferases do not 
effectively catalyze the metabolism of prizidilol. 
The cytosolic N-acetyltransferases appear to catalyze the metabolism 
of prizidilol. This proposal is supported by the following evidence: 
l. The disappearance of prizidilol with cytosol or purified cytosolic 
N-acetyltransferases from phenobarbital-pretreated rats required 
acetyl CoA and active transferase. 
2. The inhibitors of acetyltransferases,cuprous and manganese ions 
inhibited the disappearance of prizidilol in the presence of 
cytosol or purified cytosolic acetyltransferases plus acetyl CoA. 
3. K values of acetyl CoA for the acetylation of prizidilol are m 
essentially as found for the acetylation of other xenobiotics by 
these enzymes. 
131 
The metabolism of prizidilol by the acetyl transferases leads to 
the disappearance of prizidilol in incubation mixtures, but the 
products of the acetylation reaction need further investigation. 
It is shown that small amounts of a product which chromatographs 
identically to cyclic acetyl prizidilol is produced in incubation 
mixtures containing prizidilol, acetyl CoA and partially purified 
N-acetyltransferases (Fig. 44). 
If extrapolation of the results presented herein can be made, 
it is proposed that the metabolism of prizidilol by hepatic 
cytosol acetyltransferases would greatly exceed the metabolism of 
this drug by hepatic microsomal cytochrome P-450. 
The rate of metabolism of prizidilol by hepatic cytochrome P-450 as 
assessed by its V value which was ca 20 pmol/mg protein/min. In max 
comparison the V value for the acetylation of prizidilol by max 
hepatic cytosolic N-acetyltransferases was 0.5 µmol/mg protein/min. 
A comparison of these two values demonstrates that the V for - max 
acetylation is approximately 20 000 times greater than the V value max 
for metabolism of prizidilol by cytochrome P-450. Since the~ values 
for these two processes are approximately 1 µM of the V ,values max 
differ by the amount mentioned above. It would appear that acetylation 
greatly exceeds cytochrome P-450-dependentmetabolism of prizidilol. 
In addition, the levels of N-acetyltransferase in the liver in total 
amount would greatly exceed the levels of cytochrome P-450 in the liver, 
making this difference in acetylation for cytochrome P-450 metabolism 
rate even more striking. 
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B) After 60 min acetylation reaction of prizidilol 1. SK & F 93238 quinolin-3-al hydrazone (Internal 
standard) 
2. prizidilol quinolin-3-al hydrazone 
3. cyclised acetylated prizidilol 
C) Serum sample containing l) prizidilol, 2) SK & F 93238 and 3) cyclised acetylated prizidilol. 
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The metabolism of prizidilol by hepatic cytochrome P-450 appears to 
be characterized by a very high affinity, relative to other substrates 
for this enzyme,as well as a very low V value compared to other max 
substrates. The Km value,which is in the wM range compared to the Km 
value for drugs such as diphenylhydantoin (229). In contrast, however, 
the~ value for prizidilol is far lower than the Km's for a number 
of volatile anaesthetic agents such as halothane (230), enflurane (231), 
methoxyflurane (231) and isoflurane (232). For a lot of compounds the 
K values are in the mM range. The V values for the metabolism ·m max 
of prizidilol by hepatic microsomal cytochrome P-450 are extremely low 
compared to the Vmax values for the metabolism of other drugs; for 
example, the volatile anaesthetic agents have Vmax values in the range of 
1-20 nmol of product form/mg protein/min. In contrast the V value max 
for prizidilol is in the pmol range. These results indicate that if other 
drugs were present, in addition to prizidilol, the metabolis~ of 
prizidilol by hepatic microsomal cytochrome P-450 would be extremely 
slow. The interaction of prizidilol with the hepatic cytosol 
N-acetyltransferases, appears to be similar to the interaction of a 
number of other drugs. Both the K 1 s for acetyl CoA and for prizidilol m 
are similar to the corresponding values found for the metabolism of 
other drugs by the N-acetyltransferases, for example the Km for the 
acetylation of prizidilol with respect to acetyl CoA concentration was 
found to be 22 µM. The corresponding values for the metabolism of, 
for example,p-aminosalicylic acid, sulfamethazine, hydralazine, p-phenetidin 
and aniline are in the range of 20-39 µM (218). The K value for m 
prizidilol for the N-acetyltransferases was found to be approximately 
l JJM. Corresponding values for hydralazine varied from species to species 
and ranged from 2 wM in the rat to 18 µMin the human (218). 
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In contrast INH exhibited markedly higher K values in the range of m 
60-182 as a function of species (233). Therefore, it appears that 
prizidilol binds relatively tightly to the N-acetyltransferases compared 
to a number of other drugs and that it would be metabolized at an 
equivalent concentration at a more rapid rate by this group of enzymes. 
Of the three enzyme systems studied for the metabolism of prizidilol, 
it would appear that the GSH S-transferases play no role in prizidilol 
metabolism. The cytochrome P-450 enzyme system could play an 
intermediate role in prizidilol metabolism while the N-acetyltrans-
ferases are proposed to play the most important role in the transformation 
of this drug. These conclusions rest upon the observed K and V m max 
values for interaction with the enzyme systems in question. On the 
basis of our results, it is proposed that the major metabolite of 
prizidilol ~ vivo would therefore be an acetylated derivative. In 
preliminary experiments it was found that a product moving on thin layer 
chromatography identically to the cyclised acetylated derivative of 
prizidilol, was found in small quantities. It is thought that this is 
one possible metabolite from the acetyltransferases. However, it appears to 
be a minor metabolite. It could be speculated that the major metabolite 
of prizidilol ~ vivo will prove to be the N-acetylated product 
or some further metabolite thereof. 
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6. GENERAL SUMMARY AND CONCLUSIONS 
The hepatic microsomal cytochrome P-450 enzyme system has been shown 
to metabolize a number of volatile anaesthetic agents, e.g. enflurane 
(231, 232, 234), fluroxene (235), halothane (230), trichloroethylene (236) 
and a number of other drugs (229), and is also capable of metabolizing 
propranolol (233, 237), hydralazine (238). We have demonstrated that 
cytochrome P-450 also metabolizes the combination drug prizidilol. 
Prizidilol bound to two distinct sites on cytochrome P-450. At low 
concentrations (<23.7 µM) viz. the type I site (or substrate binding 
site), and at higher concentrations (24 - 190 µM) the type II site (or 
oxygen binding site) of the enzyme. Binding constants for the binding 
of prizidilol for both sites are reported. 
Prizidilol stimulated CO-inhibitable NADPH oxidation which is a decreased 
measure of cytochrome P-450 dependent metabolism. Prizidilol levels 
in the presence of hepatic microsomes plus NADPH generating system. The 
latter process was inhibited by metyrapone, SK & F 525-A and C0:02 
(80:20 v/v), which are known inhibitors of cytochrome P-450 (151). 
The role of different forms of cytochrome P-450 in the metabolism of 
prizidilol was assessed by studying the effects of different inducing 
agents on the ability of prizidilol to stimulate hepatic microsomal 
CO-inhibitable NADPH oxidation and on the disappearance of prizidilol 
for hepatic microsomal incubation mixtures. The inducing agents used 
included phenobarbital, s-naphthoflavone and pregnenolone-16a-carbonitrile. 
Time courses and Hanes plots of the loss of prizidilol allowed calcula-
tion of K and V values for all types of pretreatments. It was m max 
concluded, based on the observed effects of induction on K and V m max 
values, that several of the multiple forms of cytochrome P-450 bind and 
metabolize prizidilol. 
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The hepatic cytosol GSH S-transferases did not catalyze the metabolism 
of prizidilol. No loss of prizidilol was seen with liver cytosol 
plus GSH. Acetylation was found to play a significant role in 
prizidilol metabolism. Enzymatic acetylation of prizidilol was found 
following incubation of the substrate and acetyl CoA with rat liver 
cytosol or partially purified N-acetyltransferases. The levels of 
cyclised acetylated product were significantly increased following 
incubation. The acetylation of prizidilol was inhibited by cuprous 
chloride and manganese sulfate, which inhibit acetyltransferase. 
The Km for the acetylation of prizidilol was 0.78 llM and the maximum 
velocity of the reaction (Vmax) was 0.98 µmol/mg protein/min. 
Limiting value of the apparent Km for acetyl CoA was 22 ± 0.17 µM. 
Future directions of research will include the following: 
(a) Analysis of prizidilol metabolism by human liver microsomes -
comparison to the rat and inter-individual human differences; 
{b) Investigation of the metabolism of prizidilol in isolated rat and 
human hepatocytes in order to assess in a more physiologically 
relevant system, the biotransformation of this drug, and 
(c) Characterization of the acetylated derivatives of prizidilol. 
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